WO2023066350A1 - Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 - Google Patents

Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 Download PDF

Info

Publication number
WO2023066350A1
WO2023066350A1 PCT/CN2022/126516 CN2022126516W WO2023066350A1 WO 2023066350 A1 WO2023066350 A1 WO 2023066350A1 CN 2022126516 W CN2022126516 W CN 2022126516W WO 2023066350 A1 WO2023066350 A1 WO 2023066350A1
Authority
WO
WIPO (PCT)
Prior art keywords
dioxopiperidin
dione
alkyl
methyl
diazabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/126516
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
杨小宝
孙仁红
赵宝寅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gluetacs Therapeutics Shanghai Co Ltd
Original Assignee
Gluetacs Therapeutics Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gluetacs Therapeutics Shanghai Co Ltd filed Critical Gluetacs Therapeutics Shanghai Co Ltd
Priority to EP22882955.2A priority Critical patent/EP4421071A4/en
Priority to AU2022370021A priority patent/AU2022370021B2/en
Priority to JP2024524582A priority patent/JP2024539269A/ja
Priority to CA3235512A priority patent/CA3235512A1/en
Priority to KR1020247016562A priority patent/KR20240110576A/ko
Priority to US18/703,316 priority patent/US20250243210A1/en
Publication of WO2023066350A1 publication Critical patent/WO2023066350A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Definitions

  • the present disclosure relates to a cereblon (CRBN) E3 ubiquitin ligase ligand compound of formula (I) and formula (II), a protein degradation compound of formula (III) comprising the same, and applications thereof.
  • the CRBN E3 ubiquitin ligase ligand compound can effectively treat or prevent diseases or diseases mediated by cereblon protein.
  • the protein degrading compound of formula (III) is effective in treating or preventing diseases or conditions associated with the degraded protein.
  • the bifunctional protein degradation targeting drug consists of three parts, one end is a ligand warhead that can bind to a specific target protein, the other end is a small molecule ligand of E3 ubiquitin ligase, and the middle is connected by link units of different lengths and types.
  • Bifunctional protein-degrading small molecule compounds can use the binding effect of ligands at both ends to simultaneously bind specific target proteins and E3 ubiquitin ligases, thereby recruiting E3 ubiquitin ligases to the vicinity of specific target proteins, and enabling E3 ubiquitin ligases to The target protein is marked with ubiquitination. Target proteins marked by multiple ubiquitination are recognized and degraded by the proteasome in vivo.
  • the biggest difference of protein degradation-targeted drugs is that the whole cell is mobilized as the drug effector unit.
  • This drug mode of action only requires small molecule drugs to bind to the target protein briefly, and it is enough to label the target protein as "need to clean up". Therefore, a low concentration of drug dose can meet the requirements, greatly reducing the risk of off-target effects. And it may be able to fundamentally eliminate the tumor progression caused by the abnormal expression of the driver gene and the drug resistance caused by the acquired mutation of the driver gene.
  • E3 ubiquitin ligases involved in the design of protein degradation-targeted drugs include more than 500 different proteins, each with different cellular expression profiles, and can be divided into multiple classes according to their structural elements of E3 functional activity. At present, only a few ligases have been successfully applied to the research of preclinical degraders, and Cereblon (CRBN) E3 ubiquitin ligase is one of the most widely used E3 ubiquitin ligases.
  • CRBN-type E3 ubiquitin ligase ligands include thalidomide and its analogs pomalidomide and lenalidomide, all of which have a phthalimide skeleton.
  • CRBN-type E3 ubiquitin ligase ligands themselves can also act as molecular glues to induce degradation of specific proteins. Cereblon (CRBN) forms a functional E3 ubiquitin ligase complex with damaged DNA-binding protein 1 (DDB1) and Cullin 4 A. In the complex, CRBN functions as a substrate receptor, and molecules such as thalidomide After the glue degrading agent combines with CRBN, it will induce CRBN to recognize new substrate proteins to be ubiquitinated and further recognized and degraded by proteasome.
  • DDB1 DNA-binding protein 1
  • CRBN ligands have been widely used in protein degradation, and a series of CRBN ligand-based protein degradation small molecules that utilize the function of the CRBN E3 ubiquitin ligase complex have also been gradually developed. Since CRBN ligands can be used not only as molecular glue degraders to induce the degradation of different substrate proteins, but also as part of bifunctional protein degradation drugs to achieve effective degradation of specific disease-causing proteins, at the same time, a variety of amine compounds There are unavoidable side effects and drug resistance problems, so it is of great significance to design novel and optimized E3 ubiquitinated ligase ligands, and to study their ability to bind to CRBN and biological activity, and then apply them to biologics. Functional Protein Degradation Small Molecule Drugs.
  • the purpose of the present disclosure is to provide novel CRBN ligands, protein degradation molecules designed based on the novel CRBN ligands and various target protein ligands, their uses, and their methods of use.
  • An advantage of the compounds provided herein is that they can have a wide range of pharmacological activities through the degradation/inhibition of a variety of different pathogenic protein classes or families.
  • the present disclosure provides a novel CRBN ligand, which itself can be used as a molecular glue to bind CRBN E3 ligase, and then induce CRBN substrate proteins (including but not limited to GSPT1, IKZF1, Degradation of IKZF2, IKZF3 (Aiolos) and IKZF4 proteins).
  • CRBN substrate proteins including but not limited to GSPT1, IKZF1, Degradation of IKZF2, IKZF3 (Aiolos) and IKZF4 proteins.
  • novel CRBN ligands of the present disclosure may be compounds of formula (I) or salts, stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs or Polymorphs:
  • A represents CO, CH2 or CD2 ;
  • R 1 , R 2 , R 3 and R 4 are the same or different and independently represent, for example, hydrogen, deuterium, halogen, optionally deuterated C 1-6 alkyl, optionally deuterated C 1-6 alkane Oxygen, or halogenated C 1-6 alkyl;
  • R 5 , R 6 , R 7 and R 8 are the same or different and each independently represents, for example, R 9 , hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, optionally deuterated C 1 -6 alkyl, optionally deuterated C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, wherein R 5 , R 6 , R 1 to 3 of 7 and R 8 represent R 9 ;
  • R 9 represents a group RU-, wherein,
  • U represents a bond, or U represents N(R 10 ) or O, wherein R 10 represents, for example, H, or optionally deuterated C 1-6 alkyl;
  • R represents an optionally substituted nitrogen-containing heterocyclic group, and the optionally substituted nitrogen-containing heterocyclic group is an optionally substituted nitrogen-containing monocyclic heterocyclic group or an optionally substituted nitrogen-containing bridging heterocyclic group;
  • R 5 , R 6 , R 7 and R 8 represents R 9 and said compound of formula (I) is not deuterated:
  • R represents the optionally substituted nitrogen-containing bridged heterocyclic group
  • the compound of formula (I) does not include the following compounds:
  • R 6 and R 7 represents R 9 , wherein the group R represents a substituted nitrogen-containing monocyclic heterocyclic group, and the other of R 6 and R 7 , R 5 and R 8 are each independently represents hydrogen, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or In the case of C2-6 alkynyl, the other of R6 and R7 , 1 to 3 of R5 and R8 represent halogen, and the nitrogen-containing monocyclic heterocyclic group is replaced by one or more Substituents selected from the following substituents: hydroxyl, amino, mercapto, nitro, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, NH 2 - C 1-6 alkylene, C 1-6 alkyl-NH-, C
  • R 6 and R 7 When A represents CO and one of R 6 and R 7 represents R 9 , wherein the group R represents an unsubstituted nitrogen-containing monocyclic heterocyclic group, the other of R 6 and R 7 represents hydrogen, halogen, hydroxyl, Mercapto, nitro, amino, cyano, C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, and R 5 and R 8 each independently represent a halogen;
  • R 5 and R 8 represents R 9 , wherein the group R represents a substituted nitrogen-containing monocyclic heterocyclic group, and the other of R 5 and R 8 , R 6 and R 7 are independently represents hydrogen, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or In the case of C2-6 alkynyl, the other of R5 and R8 , 1 to 3 of R6 and R7 represent halogen, and the nitrogen-containing monocyclic heterocyclic group is replaced by one or more Substituents selected from the following substituents: hydroxyl, amino, mercapto, nitro, halogen, cyano, CHO, C 1-6 alkyl, halogenated C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 alkyl-NH-,
  • R represents an unsubstituted nitrogen-containing monocyclic heterocyclic group
  • the other of R 5 and R 8 and/or R 7 is independently represents halogen
  • R represents hydrogen, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl , C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2 -6 alkenyl, or C 2-6 alkynyl;
  • R 6 and R 7 represents R 9
  • the group R represents a substituted nitrogen-containing monocyclic heterocyclic group
  • the other of R 6 and R 7 , R 5 and R 8 are each independently represent hydrogen, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl
  • the other of R 6 and R 7 , 1 to 3 of R 5 and R 8 represent halogen
  • the nitrogen-containing monocyclic heterocyclic group is replaced by one or A plurality of substituents selected from the following substitutions: hydroxyl, amino, mercapto, nitro, halogen, CHO, cyano, C 1-6 alkyl, halogenated C 1-6 alkyl, C 3-6 cycloalkyl, C 1-6 alkoxy, C 1-6 alkyl-NH-, NH 2
  • R 6 and R 7 represents R 9 , wherein the group R represents an unsubstituted nitrogen-containing monocyclic heterocyclic group, R 5 represents halogen, the other of R 6 and R 7 and /or R 8 each independently represent halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 Alkenyl, or C 2-6 alkynyl;
  • R 5 and R 8 represents R 9 , wherein the group R represents a substituted nitrogen-containing monocyclic heterocyclic group, and the other of R 5 and R 8 , R 6 and R 7 are each independently represent hydrogen, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, the other of R 5 and R 8 , 1 to 3 of R 6 and R 7 represent halogen, and the nitrogen-containing monocyclic heterocyclic group is replaced by one or more Substituents selected from the following substituents: hydroxyl, amino, mercapto, nitro, halogen, CHO, cyano, C 1-6 alkyl, halogenated C 1-6 alkyl, C 3-6 cycloalkyl, C 1 -6 alkoxy, C 1-6 alkyl-NH-, NH
  • R 5 and R 8 represents R 9 , wherein the group R represents an unsubstituted nitrogen-containing monocyclic heterocyclic group
  • R 5 and R 8 , R 6 and R 7 Each independently represents hydrogen, halogen, hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl , or C 2-6 alkynyl
  • the other of R 5 and R 8 , R 6 and R 7 are not hydrogen at the same time, and when R 6 is halogen, the R 5 and R 8 The other and R7 are not simultaneously hydrogen.
  • the CRBN ligand of the present disclosure may be a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorphic form thereof thing:
  • A represents CO, CH2 or CD2 ;
  • R 1 , R 2 , R 3 and R 4 are the same or different and independently represent, for example, hydrogen, deuterium, halogen, optionally deuterated C 1-6 alkyl, optionally deuterated C 1-6 alkane Oxygen, or halogenated C 1-6 alkyl;
  • R b represents that the benzene ring is substituted by n R b , and each R b is the same or different and independently represents, for example, hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano, or Select deuterated C 1-6 alkyl, optional deuterated C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl;
  • R a (R a ) m means that the benzene ring is substituted by m R a , each R a is the same or different and each independently represents the following structure:
  • U 1 and U 2 are the same or different and each independently represents, for example, a bond, N(R d ) or O, wherein R d represents, for example, H or optionally deuterated C 1-6 alkyl;
  • R c represents an optionally substituted nitrogen-containing monocyclic heterocyclic group or an optionally substituted nitrogen-containing bridging heterocyclic group
  • W represents hydrogen, an optionally substituted nitrogen-containing monocyclic heterocyclic group, an optionally substituted nitrogen-containing bridging heterocyclic group, an optionally substituted cycloalkyl group, an optionally substituted heteroaryl group, an optionally substituted aryl group, C 2-6 alkenyl, C 2-6 alkynyl, leaving group, CHO, COOH, NH 2 , hydroxyl, or mercapto; and
  • W represents an optionally substituted nitrogen-containing monocyclic heterocyclic group, an optionally substituted nitrogen-containing bridged heterocyclic group, an optionally substituted cycloalkyl group, an optionally substituted heteroaryl group or an optionally substituted aryl group
  • LIN represents a bond, an optionally substituted methylene group, or an optionally substituted linear or branched C 2-30 alkylene group, wherein the main carbon of the linear or branched C 2-30 alkylene group is One or more groups R e and/or one or more groups R f or any combination of one or more groups R e and R f may optionally be inserted into the chain, said groups R e , R f Or the combination of the group R e and R f breaks the carbon-carbon bond between one or more pairs of adjacent carbon atoms of the main carbon chain; each group R e is selected from O, N(R g ), C(O), C(O)O, OC(O), S(O), S(O) 2 ,
  • LIN represents optionally substituted methylene, or optionally substituted A linear or branched C 2-30 alkylene group, wherein the main carbon chain of the linear or branched C 2-30 alkylene group is optionally inserted with one or more groups R e and/ Or one or more groups R f or any combination of one or more groups R e and R f , the group R e , R f or the combination of groups R e and R f will make the main carbon chain
  • each group R e is selected from O, N(R g ), C(O), C(O)O, OC(O), S(O), S(O) 2 , S(O) 2 NH, NHS(O) 2 , C(O)N(R g ), N(R
  • LIN represents an optionally substituted methylene group
  • W represents an optionally substituted nitrogen-containing monocyclic heterocyclic group or an optionally substituted nitrogen-containing bridged heterocyclic group
  • n represents an integer 0, 1, 2, or 3
  • the sum of m and n is an integer 1, 2, 3 or 4; provided that, when the compound of formula (II) When not being deuterated, the compound of formula (II) is not the following compound:
  • the protein degrading molecules of the present disclosure are compounds of formula (III) or salts, stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs or polymorphs thereof :
  • PBM-R 1 -W 1 - represents the targeting moiety capable of binding protein
  • ULM represents the ligand moiety capable of binding E3 ubiquitin ligase
  • LIN is the linking moiety
  • PBM-R 1 -W 1 - co-operates with the group LIN Valence connect ULM;
  • ULM represents the structure of the following formula (ULM):
  • A represents CO, CH2 or CD2 ;
  • R 1 , R 2 , R 3 and R 4 are the same or different and independently represent, for example, hydrogen, deuterium, halogen, optionally deuterated C 1-6 alkyl, optionally deuterated C 1-6 alkane Oxygen, or halogenated C 1-6 alkyl;
  • R b n means that the benzene ring is optionally substituted by n R b , and each R b is the same or different and each independently represents, for example, hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino, cyano Group, optional deuterated C 1-6 alkyl, optional deuterated C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl ;
  • n represents the integer 0, 1, 2 or 3;
  • U 1 and U 2 are the same or different and each independently represents, for example, a bond, N(R d ) or O, wherein R d represents, for example, H or optionally deuterated C 1-6 alkyl;
  • R c represents an optionally substituted nitrogen-containing monocyclic heterocyclic group or an optionally substituted nitrogen-containing bridging heterocyclic group
  • LIN represents a bond, an optionally substituted methylene group, or an optionally substituted linear or branched C 2-30 alkylene group, wherein the main carbon of the linear or branched C 2-30 alkylene group is One or more groups R e and/or one or more groups R f or any combination of one or more groups R e and R f may optionally be inserted into the chain, said groups R e , R f Or the combination of the group R e and R f breaks the carbon-carbon bond between one or more pairs of adjacent carbon atoms of the main carbon chain; each group R e is selected from O, N(R g ), C(O), C(O)O, OC(O), S(O), S(O) 2 , S(O) 2 NH, NHS(O) 2 , C(O)N(R g ), N(R g )C(O), or N(R g )C(O)N(R g ), wherein each R g independently represents H or C
  • W 1 is t connected rings W 2 represented by the following structural formula:
  • Each ring W is the same or different and each independently is an optionally substituted nitrogen-containing monocyclic heterocyclylene, an optionally substituted nitrogen-containing bridged heterocyclylene, or an optionally substituted cycloalkylene, and
  • t represents the integer 1 or 2;
  • R1 means:
  • C 1-6 alkylene eg methylene
  • R 1a is hydrogen or C 1-6 alkyl
  • R 2a is optionally substituted C 1-6 alkylene or optionally substituted C 2- 6 alkenylene
  • each R 3a is the same or different and each independently is, for example, halogen, hydroxyl, cyano, amino, nitro, C 1-6 alkyl , halogenated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy;
  • one or more hydrogens of the compound of formula (III) are optionally replaced by deuterium;
  • the compound of formula (III) when the compound of formula (III) is not substituted by deuterium, the compound of formula (III) does not include the following compounds:
  • R 1 represents a bond
  • W 1 represents a piperidinylene group
  • LIN represents a methylene group
  • R c represents a piperazinylene group, 2,5-diazabicyclo[2.2.1]heptane Alkylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene
  • R b represents Fluorine
  • n represents an integer 1, 2 or 3
  • U1 and U2 are the same or different and each independently represents a bond, NH or O; or
  • R 1 represents a bond
  • W 1 represents a piperazinylene group
  • LIN represents a methylene group
  • R c represents a piperidinylene group, 2,5-diazabicyclo[2.2.1]heptane Alkylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene
  • R b represents Fluorine
  • n represents an integer 1, 2 or 3
  • U 1 and U 2 are the same or different and each independently represents a bond, NH or O;
  • R 1 represents a bond
  • W 1 represents piperidinylene
  • LIN represents methylene
  • R c represents piperazinylene, 2,5-diazabicyclo[2.2.1]heptane Alkylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene
  • R b represents Fluorine
  • n represents an integer 1, 2 or 3
  • U1 and U2 are the same or different and each independently represents a bond, NH or O; or
  • R 1 represents a bond
  • W 1 represents a piperazinylene group
  • LIN represents a methylene group
  • R c represents a piperidinylene group, 2,5-diazabicyclo[2.2.1]heptane Alkylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene
  • R b represents Fluorine
  • n represents an integer 1, 2 or 3
  • U 1 and U 2 are the same or different and each independently represents a bond, NH or O;
  • R 1 represents a bond or -O-CH 2 -CH 2 -
  • W 1 represents piperidinylene
  • LIN represents methylene
  • R c represents piperazinylene, 2,5- Diazabicyclo[2.2.1]heptaneylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3. 1] nonane subgroup
  • R represents hydrogen
  • U and U are identical or different and each independently represents a bond, NH or O; or
  • R 1 represents a bond or -O-CH 2 -CH 2 -
  • W 1 represents piperazinylene
  • LIN represents methylene
  • R c represents piperidinylene, 2,5- Diazabicyclo[2.2.1]heptaneylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3. 1] nonane subgroup
  • R b represents hydrogen
  • U 1 and U 2 are the same or different and each independently represents a bond, NH or O;
  • R 1 represents a bond or represents -O-CH 2 -CH 2 -
  • W 1 represents piperidinylene
  • LIN represents methylene
  • R c represents piperazinylene, 2,5 -Diazabicyclo[2.2.1]heptaneylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3 .1]
  • Nonaneylidene R b represents hydrogen
  • U 1 and U 2 are the same or different and each independently represents a bond, NH or O; or
  • R 1 represents a bond or represents -O-CH 2 -CH 2 -
  • W 1 represents piperazinylene
  • LIN represents methylene
  • R c represents piperidinylene, 2,5 -Diazabicyclo[2.2.1]heptaneylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3 .1]
  • Nonaneylidene R b represents hydrogen
  • U 1 and U 2 are the same or different and each independently represents a bond, NH or O.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorphs, and at least one pharmaceutically acceptable carrier.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorphs, and at least one pharmaceutically acceptable carrier.
  • the present disclosure provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (III) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorphs, and at least one pharmaceutically acceptable carrier.
  • kits or kit comprising:
  • a compound of formula (I) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising it; or
  • a compound of formula (II) or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising it; or
  • the present disclosure provides a compound of formula (I) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof or comprising the same as A pharmaceutical composition of active ingredients for use as a medicament.
  • the present disclosure further provides compounds of formula (I) or salts, stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs or polymorphs thereof or comprising A pharmaceutical composition as an active ingredient for treating or preventing diseases or conditions mediated by cereblon protein.
  • the diseases or conditions mediated by the cereblon protein include, but are not limited to, tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, anemia, Hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, congestive heart failure, myocardial infarction, Onwerichter's syndrome, Richter's syndrome (Richter syndrome, RS), acute liver failure or diabetes.
  • tumors infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, anemia, Hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, congestive heart failure, myocardial infarction, Onwerichter's syndrome, Richter's syndrome (Richter syndrome, RS), acute liver failure or diabetes.
  • MODS multiple organ dysfunction syndrome
  • sarcoidosis sarcoidosis
  • adult respiratory distress syndrome congestive heart failure
  • the present disclosure provides a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof or comprising the same as A pharmaceutical composition of active ingredients for use as a medicament.
  • the present disclosure further provides compounds of formula (II) or salts, stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs or polymorphs thereof or comprising A pharmaceutical composition as an active ingredient for treating or preventing diseases or conditions mediated by cereblon protein.
  • the present disclosure provides a compound of formula (III) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof or comprising the same as A pharmaceutical composition of active ingredients for use as a medicament.
  • the present disclosure further provides compounds of formula (III) or salts, stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs or polymorphs thereof or comprising Pharmaceutical composition as an active ingredient for the treatment and/or prophylaxis of a disease or condition selected from the group consisting of tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases , anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, congestive heart failure, myocardial infarction, Wengwerricht syndrome, Richter Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin disease, cardiovascular disease, dysfunctional uterine bleeding, anemia, pediatric aplastic Anemia, endometriosis, transplant rejection, polycystic ovary syndrome, or thyroid disease.
  • a disease or condition selected from the group consisting
  • the present disclosure provides a compound of formula (I) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof for use in the preparation of the present invention
  • a compound of formula (I) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof for use in the preparation of the present invention
  • the present disclosure also provides the use of a compound of formula (I) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph for the preparation of the present invention.
  • Disclosed methods are compounds of formula (III) or salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs thereof.
  • the present disclosure provides a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof for use in the preparation of the present invention
  • a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph thereof for use in the preparation of the present invention
  • the present disclosure also provides the use of a compound of formula (II) or a salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug, or polymorph for the preparation of the present invention.
  • Disclosed methods are compounds of formula (III) or salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs thereof.
  • the present disclosure also provides compounds of formula (I) or salts, stereoisomers (including enantiomers), solvates, isotopically enriched analogs, prodrugs or polymorphs thereof for the preparation of Use of a medicament for treating or preventing a disease or condition mediated by a cereblon protein.
  • the present disclosure also provides a compound of formula (II) or a salt thereof, a stereoisomer (including an enantiomer), a solvate, an isotopically enriched analog, a prodrug or a polymorph for preparing Use of a medicament for treating or preventing a disease or condition mediated by a cereblon protein.
  • the present disclosure also provides a compound of formula (III) or its salt, stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph for the preparation of Use of a medicament for the treatment and/or prevention of a disease or condition selected from the group consisting of tumors, infectious diseases, autoinflammatory diseases, inflammatory diseases, autoimmune diseases, neurological diseases, respiratory diseases, anemia, hemorrhagic shock, Transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoidosis, adult respiratory distress syndrome, congestive heart failure, myocardial infarction, Wengwericht syndrome, Richter syndrome (Richter syndrome, RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin disease, cardiovascular disease, dysfunctional uterine bleeding, anemia, pediatric aplastic anemia, endometriosis syndrome, transplant rejection, polycystic ovary syndrome, or thyroid disease.
  • a disease or condition selected from the group consist
  • the present disclosure also provides a method for treating or preventing a disease or condition mediated by a cereblon protein in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I), or Salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs thereof, or pharmaceutical compositions comprising them.
  • the present disclosure also provides a method for treating or preventing a disease or condition mediated by a cereblon protein in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (II), or Salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs thereof, or pharmaceutical compositions comprising them.
  • a method for treating or preventing a disease or condition mediated by a cereblon protein in a subject comprising administering to the subject a therapeutically effective amount of a compound of formula (II), or Salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or polymorphs thereof, or pharmaceutical compositions comprising them.
  • the present disclosure also provides a method of treating or preventing a disease or condition in a subject, wherein the disease or condition comprises a tumor, an infectious disease, an autoinflammatory disease, an inflammatory disease, an autoimmune disease , neurological disease, respiratory disease, anemia, hemorrhagic shock, transplant rejection, multiple organ dysfunction syndrome (MODS), sarcoid disease, adult respiratory distress syndrome, congestive heart failure, myocardial infarction, Unwerich Tetra syndrome, Richter syndrome (RS), acute liver failure, diabetes, Kennedy disease, seborrheic alopecia, hirsutism, skin disease, cardiovascular disease, dysfunctional uterine bleeding , anemia, aplastic anemia in children, endometriosis, transplant rejection, polycystic ovary syndrome, and thyroid disease, the method comprising administering a therapeutically effective amount of a compound of formula (III) or Salts, enantiomers, stereoisomers, solvates, isotopically enriched analogs, prodrugs or poly
  • Figure 1 shows that the compound of the present invention can effectively inhibit the proliferation of tumor cell line DU-145, and the inhibitory effect is better than that of the positive control drug enzalutamide.
  • Figure 2 shows the degradative ability of the compounds of the present invention to full-length androgen receptor (AR-FL) and androgen receptor splice variant 7 (AR-V7) proteins in human prostate cancer cell 22RV1 detected by Western-blot.
  • AR-FL full-length androgen receptor
  • AR-V7 androgen receptor splice variant 7
  • Fig. 3 shows the ability of the compound of the present invention to degrade the full-length androgen receptor (AR-FL) protein in human prostate cancer cell C4-2 detected by Western-blot.
  • the present disclosure provides a compound of formula (I) or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph Model:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined above for the compound of formula (I).
  • R 1 , R 2 , R 3 and R 4 of the compound of formula (I) are the same or different and each independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), optionally deuterium Substituted C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl) , optionally deuterated C 1-6 alkoxy (such as optionally deuterated C 1-4 alkoxy, such as methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy group, butoxy, sec-butyloxy or tert-butyloxy), or halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH
  • R 1 , R 2 , R 3 and R 4 of the compound of formula (I) are the same or different and each independently represent hydrogen or deuterium.
  • R 1 , R 2 , R 3 and R 4 of the compound of formula (I) represent hydrogen.
  • a of the compound of formula (I) represents CO.
  • a of the compound of formula (I) represents CH2 .
  • a of the compound of formula (I) represents CD2 .
  • the formula (I) compounds are optionally partially deuterated, for example carrying 1 to 20 (eg 1-15, 1-10, 1-6, 1-5, 1-4, 1-3, 1-2, or 1) deuterium, or the compound of formula (I) is optionally fully deuterated.
  • the number of deuterium atoms is in principle not subject to any restrictions or is automatically limited by the size of the building blocks.
  • R 9 when only one of R 5 , R 6 , R 7 and R 8 of a compound of formula (I) represents R 9 , said compound of formula (I) is partially deuterated, for example carrying 1 to 15 (eg, 1-10, 1-6, 1-5, 1-4, 1-3, 1-2, or 1) deuterium, or the compound of formula (I) is fully deuterated.
  • the number of deuterium atoms is in principle not subject to any restrictions or is automatically limited by the size of the building blocks.
  • R 5 of the compound of formula (I) represents R 9
  • R 6 , R 7 and R 8 are the same or different and independently represent hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino , cyano, optional deuterated C 1-6 alkyl, optional deuterated C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 Alkynyl.
  • R 6 of the compound of formula (I) represents R 9
  • R 5 , R 7 and R 8 are the same or different and independently represent hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino , cyano, optional deuterated C 1-6 alkyl, optional deuterated C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 Alkynyl.
  • R 7 of the compound of formula (I) represents R 9
  • R 5 , R 6 and R 8 are the same or different and independently represent hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino , cyano, optional deuterated C 1-6 alkyl, optional deuterated C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 Alkynyl.
  • R 8 of the compound of formula (I) represents R 9
  • R 5 , R 6 and R 7 are the same or different and independently represent hydrogen, deuterium, halogen, hydroxyl, mercapto, nitro, amino , cyano, optional deuterated C 1-6 alkyl, optional deuterated C 1-6 alkoxy, halogenated C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 Alkynyl.
  • R 5 , R 6 , R 7 and R 8 in a compound of formula (I) represents R 9 and said compound of formula (I) is not deuterated
  • R represents When the optionally substituted nitrogen-containing bridged heterocyclic group, the compound of formula (I) does not include the following compounds:
  • R 5 , R 6 , R 7 and R 8 in a compound of formula (I) represents R 9 and said compound of formula (I) is not deuterated
  • A represents CO
  • the group R represents a substituted nitrogen-containing monocyclic heterocyclic group
  • the other of R 6 and R 7 , R 5 and R 8 each independently represent hydrogen , halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), C 1-6 alkoxy (e.g.
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy, isopropoxy , butoxy, sec-butyloxy or tert-butyloxy
  • halogenated C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH -, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), C 2-6
  • alkenyl such as vinyl, propenyl or butynyl
  • C 2-6 alkynyl such as ethynyl, propynyl or butynyl
  • the other of R6 and R7 , R 1 to 3 (eg 1, 2 or 3) of 5 and R 8 represent halogen, and the nitrogen-containing monocyclic heterocyclic group is replaced by one
  • R 6 and R 7 and R 8 in a compound of formula (I) represents R 9 and said compound of formula (I) is not deuterated
  • A represents One of CO and R 6 and R 7 represents R 9
  • the other of R 6 and R 7 represents hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, secondary butyl or tert-butyl), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyl oxy or tert-butyloxy), halogenated C 1-6
  • R and R each independently represent halogen (such as fluorine, chlorine, bromine or iodine).
  • R 5 , R 6 , R 7 and R 8 in a compound of formula (I) represents R 9 and said compound of formula (I) is not deuterated
  • A represents CO
  • one of R 5 and R 8 represents R 9
  • the group R represents a substituted nitrogen-containing monocyclic heterocyclic group
  • the other of R 5 and R 8 , R 6 and R 7 each independently represent hydrogen , halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), C 1-6 alkoxy (e.g.
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy, isopropoxy , butoxy, sec-butyloxy or tert-butyloxy
  • halogenated C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH -, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), C 2-6
  • alkenyl such as vinyl, propenyl or butynyl
  • C 2-6 alkynyl such as ethynyl, propynyl or butynyl
  • the other of R 5 and R 8 , R 1 to 3 (eg 1, 2 or 3) of 6 and R 7 represent halogen (eg fluorine, chlorine, bromine or iodine
  • R 5 , R 6 , R 7 and R 8 in a compound of formula (I) represents R 9 and said compound of formula (I) is not deuterated
  • A represents CO and one of R 5 and R 8 represents R 9
  • the other of R 5 and R 8 and/or R 7 each independently represents a halogen
  • R represents hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), C 1-6 alkoxy (e.g.
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy group, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • halogenated C 1-6 alkyl eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -
  • C 2-6 alkenyl eg vinyl, propenyl or butenyl
  • C 2-6 alkynyl eg ethynyl, propynyl or butynyl.
  • R 5 , R 6 , R 7 and R 8 in a compound of formula (I) represents R 9 and said compound of formula (I) is not deuterated
  • A represents CH 2 and one of R 6 and R 7 represent R 9
  • the group R represents a substituted nitrogen-containing monocyclic heterocyclic group
  • the other of R 6 and R 7 , R 5 and R 8 each independently represent Hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl , isopropyl, butyl, sec-butyl or tert-butyl), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy butoxy, sec-butyloxy or tert-butyl
  • 1-6 e.g. 1, 2, 3, 4, 5 or 6) substituents selected from the group consisting of hydroxy, amino, mercapto, nitro, halogen (e.g. fluorine, chlorine, bromine or iodine), CHO, cyano, C 1-6 alkyl (e.g. C 1-4 alkyl, e.g. methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1 -6 alkyl (e.g.
  • halogenated C 1-4 alkyl such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), C 3-6 cycloalkyl (eg cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), C 1-6 alkoxy (e.g. C1-4 alkoxy, e.g.
  • C 1-6 alkyl-NH- such as C 1-3 alkyl NH-, such as CH 3 NH-, CH 3 CH 2 NH- or CH 3 CH 2 CH 2 NH-
  • NH 2 -C 1- 6 alkylene eg NH 2 -C 1-3 alkylene-, eg NH 2 CH 2 -, NH 2 CH 2 CH 2 - and NH 2 CH 2 CH 2 CH 2 -
  • C 1-6 alkyl -NHC(O)- such as CH 3 -NHC(O)-, CH 3 CH 2 -NHC(O)-, and CH 3 CH 2 CH 2 -NHC(O)-
  • C 1-6 alkyl- C(O)NH- eg, CH3 -C( O )NH-, CH3CH2 -C(O)NH-, and CH3CH2CH2 - C
  • R 5 represents halogen (such as fluorine, chlorine, bromine or iodine)
  • R 6 and The other in R 7 and/or R 8 each independently represent halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl (such as C 1-6 4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy ethoxy, propoxy, iso
  • R 5 , R 6 , R 7 and R 8 in a compound of formula (I) represents R 9 and said compound of formula (I) is not deuterated
  • A represents CH 2 and one of R 5 and R 8 represent R 9
  • the group R represents a substituted nitrogen-containing monocyclic heterocyclic group
  • the other of R 5 and R 8 , R 6 and R 7 each independently represent Hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl , isopropyl, butyl, sec-butyl or tert-butyl), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy butoxy, sec-butyloxy or tert-butyl
  • R 5 , R 6 , R 7 and R 8 in a compound of formula (I) represents R 9 and said compound of formula (I) is not deuterated
  • A represents One of CH 2 and R 5 and R 8 represents R 9
  • the group R represents an unsubstituted nitrogen-containing monocyclic heterocyclic group
  • the other of R 5 and R 8 , R 6 and R 7 are each independently Represents hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro, amino, cyano, C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl radical, isopropyl, butyl, sec-butyl or tert-butyl), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropyl oxy, butoxy, sec-butyl
  • the group R of the compound of formula (I) R 9 represents an optionally substituted nitrogen-containing heterocyclic group, and the optionally substituted nitrogen-containing heterocyclic group is an optionally substituted nitrogen-containing mono Ring heterocyclyl or optionally substituted nitrogen-containing bridged heterocyclyl.
  • the nitrogen-containing monocyclic heterocyclyl is a 4- to 10-membered monocyclic heterocyclyl containing one nitrogen atom and optionally a heteroatom selected from nitrogen, oxygen and sulfur, including but Not limited to the following groups: piperidinyl, piperazinyl, morpholinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, thiomorpholine radical, azepanyl, diazepanyl, azacyclooctyl or diazepanyl.
  • the nitrogen-containing bridged heterocyclic group is a C5-20 bridged heterocyclic group containing a nitrogen atom and optionally a heteroatom selected from nitrogen, oxygen and sulfur, including but not limited to the following Group: azabicyclo[3.1.1]heptyl, azabicyclo[2.2.1]heptyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl , diazabicyclo[3.1.1]heptyl, diazabicyclo[2.2.1]heptanyl, diazabicyclo[3.2.1]octyl or diazabicyclo[2.2.2]octane Alkyl, for example, represents the following groups:
  • the nitrogen-containing monocyclic heterocyclic group and the nitrogen-containing bridging heterocyclic group are optionally substituted.
  • the nitrogen-containing monocyclic heterocyclic group and the nitrogen-containing bridging heterocyclic group are optionally replaced by one or more (for example, 1-10, 1-8 or 1-6, For example 1, 2, 3, 4, 5 or 6) are substituted with substituents selected from the group consisting of deuterium, hydroxyl, amino, mercapto, nitro, halogen (eg fluorine, chlorine, bromine or iodine), cyano, CHO, Optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert butyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-
  • the group R of the compound of formula (I) represents the following groups:
  • the compound of formula (I) is also a compound of formula (I-1) or formula (I-2):
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined above for the compound of formula (I).
  • the compound of formula (I) is also a compound of formula (I-3), formula (I-4), or formula (I-5):
  • the present disclosure provides a compound of formula (II) or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph Model:
  • R 1 , R 2 , R 3 and R 4 of the compound of formula (II) are the same or different and each independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), optionally deuterium Substituted C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl) , optionally deuterated C 1-6 alkoxy (such as optionally deuterated C 1-4 alkoxy, such as methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy group, butoxy, sec-butyloxy or tert-butyloxy), or halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, Cl
  • R 1 , R 2 , R 3 and R 4 of the compound of formula (II) are the same or different and each independently represents hydrogen or deuterium.
  • R 1 , R 2 , R 3 and R 4 of the compound of formula (II) represent hydrogen.
  • a of the compound of formula (II) represents CO.
  • a of the compound of formula (II) represents CH2 .
  • a of the compound of formula (II) represents CD2 .
  • n of the compound of formula (II) represents the integer 1
  • n represents the integer 0, 1, 2, or 3.
  • n of the compound of formula (II) represents the integer 2
  • n represents the integer 0, 1 or 2.
  • LIN represents a bond, optionally substituted methylene, or optionally substituted linear or branched C 2-30 alkylene, wherein one or more (such as 1-10, 1-8 or 1- 6, such as 1, 2, 3, 4, 5 or 6) groups R e and/or one or more (such as 1-10, 1-8 or 1-6, such as 1, 2, 3, 4, 5 or 6) groups R f or one or more (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) groups Any combination of the group Re and R f , the group Re , R f or the combination of the group Re and R f will be one or more pairs of the main carbon chain (such as 1-10 pairs,
  • W represents an optionally substituted nitrogen-containing monocyclic heterocyclic group
  • W represents an optionally substituted nitrogen-containing monocyclic heterocyclic group
  • LIN represents a bond, an optionally substituted methylene group, or an optional Substituted linear or branched C 2-30 alkylene, wherein one or more (for example 1-10 one, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) groups R e and/or one or more (for example 1-10, 1-8 or 1 -6, eg 1,2,3,4,5 or 6) groups R f or one or more (eg 1-10, 1-8 or 1-6, eg 1,2,3 , 4, 5 or 6) any combination of groups Re and R f , the group Re ,
  • optionally deuterated C 1-4 alkoxy such as methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • optionally deuterated C 1-6 alkyl-NH- such as optionally deuterated C 1-3 alkyl NH-, such as CH 3 NH-, CH 3 CH 2 NH- or CH 3 CH 2 CH 2 NH-
  • halogenated C 1-6 alkyl eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -
  • NH 2 -C 1-6 alkylene eg NH 2 -C 1-3 alkylene-, such as NH 2 CH 2 -
  • methylene group and the linear or branched C2-30 alkylene group are optionally replaced by one or more (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) are substituted with substituents selected from the group consisting of deuterium, hydroxyl, amino, mercapto, nitro, halogen (eg fluorine, chlorine, bromine or iodine), cyano, optionally deuterated C 1-6 alkyl (e.g.
  • optionally deuterated C 1-4 alkyl such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl
  • halogen Substituted C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -
  • optionally deuterated C 3-6 cycloalkyl such as optionally perdeuterated cyclopropyl , optional perdeuterated cyclobutyl, optional perdeuterated cyclopentyl or optional perdeuterated cyclohexyl
  • optionally deuterated C 1-6 alkoxy such as optionally deuterated C 1-4 alkoxy, such
  • LIN represents optionally substituted methylene, or optionally substituted linear or branched C 2-30 alkylene, wherein the linear or branched One or more (such as 1-10, 1-8 or 1-6, such as 1, 2, 3, 4, 5 or 6) can optionally be inserted into the main carbon chain of C 2-30 alkylene ) group R e and/or one or more (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) groups R f or one or Any combination of multiple (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) groups R e and R f , said group R e , R f or the combination of group R e and R f will be one or more pairs
  • C 1-6 alkoxy e.g. optionally deuterated C 1-4 alkoxy, e.g. methoxy, CD 3 -O-, ethoxy, propoxy , isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • optionally deuterated C 1-6 alkyl-NH- such as optionally deuterated C 1-3 alkane -NH-, such as CH 3 NH-, CH 3 CH 2 NH- or CH 3 CH 2 CH 2 NH-
  • halogenated C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -
  • NH- optionally deuterated C 1-6 alkyl-NH-
  • LIN represents optionally substituted methylene, or optionally substituted linear or branched C 2-30 alkylene, wherein One or more (such as 1-10, 1-8 or 1-6, such as 1, 2, 3 , 4, 5 or 6) groups R e and/or one or more (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) Group R f or any combination of one or more (eg 1-10, 1-8 or 1-6, eg 1, 2, 3, 4, 5 or 6) groups R e and R f , the group R e , R f or the combination of the group R e and R f combine one or more pairs of the main carbon chain (for example 1-10 pairs
  • deuterated C 1-4 alkyl such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl
  • deuterated C 3-6 Cycloalkyl e.g.
  • methylene group and the linear or branched C2-30 alkylene group are optionally replaced by one or more (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) are substituted with substituents selected from the group consisting of deuterium, hydroxyl, amino, mercapto, nitro, halogen (eg fluorine, chlorine, bromine or iodine), cyano, optionally deuterated C 1-6 alkyl (e.g.
  • optionally deuterated C 1-4 alkyl such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl
  • halogen Substituted C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -
  • optionally deuterated C 3-6 cycloalkyl such as optionally perdeuterated cyclopropyl , optional perdeuterated cyclobutyl, optional perdeuterated cyclopentyl or optional perdeuterated cyclohexyl
  • optionally deuterated C 1-6 alkoxy such as optionally deuterated C 1-4 alkoxy, such
  • LIN represents optionally substituted methylene
  • W represents optionally substituted nitrogen-containing monocyclic heterocyclyl or optionally substituted nitrogen-containing monocyclic heterocyclyl or Nitrogen-bridged heterocyclyl
  • methylene group is optionally substituted by one or more (eg 1 or 2) substituents selected from the group consisting of deuterium, hydroxyl, amino, mercapto, nitro, halogen (eg fluorine, chlorine, bromine or iodine ), cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH -, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), optionally deuterated C 1-6 al
  • optionally deuterated C 1-4 alkoxy e.g. methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • optionally deuterated C 1-6 alkyl-NH- such as optionally deuterated C 1-3 alkyl-NH-, such as CH 3 NH-, CH 3 CH 2 NH- or CH 3 CH 2 CH 2 NH-
  • NH 2 -C 1-6 alkylene eg NH 2 -C 1-3 alkylene-, eg NH 2 CH 2 -, NH 2 CH 2 CH 2 - and NH 2 CH 2 CH 2 CH 2 -
  • optionally deuterated C 1-6 alkyl-NHC(O)- such as optionally deuterated C 1-4 alkyl-NHC(O)-,
  • R represents piperazinyl
  • W represents optionally substituted nitrogen-containing mono
  • the piperazinyl is substituted.
  • the piperazinyl represented by R c is substituted with 1-4 (eg 1-3 or 1-2, eg 1, 2, 3 or 4) substituents selected from the group consisting of deuterium, Hydroxy, amino, mercapto, nitro, halogen (e.g. fluorine, chlorine, bromine or iodine), cyano, CHO, optionally deuterated C1-6 alkyl (e.g.
  • optionally deuterated C1-4 alkyl such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl
  • halogenated C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -
  • optionally deuterated C 3-6 cycloalkyl such as optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl or optionally perdeuterated cyclohexyl
  • optionally deuterated C 1-6 alkoxy such as optionally deuterated C 1-4 alkoxy, such as me
  • the methylene represented by LIN is optionally substituted with one or more (e.g., 1 or 2) substituents selected from the group consisting of deuterium, hydroxyl, amino, mercapto, nitro, halogen (e.g., fluoro , chlorine, bromine or iodine), cyano, optionally deuterated C 1-6 alkyl (e.g.
  • optionally deuterated C 1-4 alkyl such as methyl, CD 3 , ethyl, propyl, iso propyl, butyl, sec-butyl or tert-butyl
  • halogenated C 1-6 alkyl eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -
  • optionally deuterated C 3 -6 cycloalkyl such as optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl or optionally perdeuterated cyclohexyl
  • optionally deuterated Substituted C 1-6 alkoxy such as optionally deuterated C
  • the nitrogen-containing monocyclic heterocyclic group represented by W is optionally replaced by one or more (such as 1-10, 1-8 or 1-6, such as 1, 2, 3, 4, 5 or 6) substituents selected from the group consisting of deuterium, hydroxyl, amino, mercapto, nitro, halogen (eg fluorine, chlorine, bromine or iodine), cyano, CHO, COOH, N 3 , methanesulfonyloxy Base, trifluoromethanesulfonyloxy, p-toluenesulfonyloxy, C 1-6 alkyl, deuterated C 1-6 alkyl, halogenated C 1-6 alkyl, optionally substituted C 3-8 Cycloalkyl (such as one or more, such as 1-6, such as 1, 2, 3, 4, 5 or 6, selected from deuterium, halogen, amino, hydroxyl, mercapto, cyano, CHO, COOH, Substituents of N 3
  • R c of the compound of formula (II) represents the following groups:
  • a monocyclic C3-10 heterocyclylene containing a nitrogen atom and optionally a heteroatom selected from nitrogen, oxygen and sulfur for example, piperidinylene, piperazinylene, morpholinylene, nitrogenous Heterocyclobutyl, pyrrolidinylene, imidazolidinylene, pyrazolidinylene, oxazolidinyl, thiazolidinylene, thiomorpholinyl, azepanylidene, diazepine Heptylidene, azacyclooctylene or diazacyclooctylene; or
  • azabicyclo[3.1.1]heptaneylidene azabicyclo[2.2 .1] heptaneylidene, azabicyclo[3.2.1]octanylidene, azabicyclo[2.2.2]octanylidene, diazabicyclo[3.1.1]heptaneylidene, diazo Heterobicyclo[2.2.1]heptaneylidene, diazabicyclo[3.2.1]octanylidene or diazabicyclo[2.2.2]octanylidene, for example the following groups:
  • the monocyclic C 3-10 heterocyclylene and the C 5-20 bridged heterocyclylene are each independently optionally replaced by one or more (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) are substituted with substituents selected from the group consisting of deuterium, hydroxyl, amino, mercapto, nitro, halogen (such as fluorine, chlorine, bromine or iodine), cyano, CHO, Deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl group), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CH
  • R c of the compound of formula (II) represents the following groups:
  • W of the compound of formula (II) represents the following groups:
  • a monocyclic C3-10 heterocyclic group containing a nitrogen atom and optionally a heteroatom selected from nitrogen, oxygen and sulfur for example, piperidinyl, piperazinyl, morpholinyl, azetidinyl, Pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, thiomorpholinyl, azepanyl, diazepanyl, azacyclooctyl, or diazepine Cyclooctyl; or
  • a C5-20 bridged heterocyclic group containing a nitrogen atom and optionally a heteroatom selected from nitrogen, oxygen and sulfur for example, azabicyclo[3.1.1]heptanyl, azabicyclo[2.2.1 ]heptyl, azabicyclo[3.2.1]octyl, azabicyclo[2.2.2]octyl, diazabicyclo[3.1.1]heptanyl, diazabicyclo[2.2.1] ]heptyl, diazabicyclo[3.2.1]octyl or diazabicyclo[2.2.2]octyl, such as the following groups:
  • Saturated or partially unsaturated monocyclic or bicyclic or polycyclic C 3-20 cycloalkyl for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl , cyclooctyl, decahydronaphthyl, octahydrocyclopentadienyl, octahydro-1H-indenyl, C 7-11 spirocycloalkyl, adamantyl, noradamantyl, bornyl, bicyclic [2.2.1]heptyl or bicyclo[2.2.1]heptenyl; or
  • Heteroaryl for example, a 5- to 20-membered monocyclic ring containing 1 or more (eg 1-4, eg 1, 2, 3 or 4) heteroatoms independently selected from oxygen, nitrogen and sulfur or Bicyclic C5-20 aromatic ring groups, for example, furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazole Base, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuryl, isobenzofuryl, benzothienyl, indole Azolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl
  • C5-14 aryl optionally comprising one or more (eg 1-3, eg 1, 2 or 3) fused rings, eg, phenyl or naphthyl or fluorenyl; and
  • the monocyclic C 3-10 heterocyclic group, the C 5-20 bridged heterocyclic group, the C 3-20 cycloalkyl, the heteroaryl and the C 5-14 aryl are each independently Optionally substituted with one or more (e.g. 1-10, 1-8 or 1-6, e.g.
  • perdeuterated C 1-3 alkyl-NH- such as CD 3 NH-, CD 3 CD 2 NH- or CD 3 CD 2 CD 2 NH-
  • NH 2 -C 1-6 alkylene eg NH 2 -C 1-3 alkylene-, eg NH 2 CH 2 -, NH 2 CH 2 CH 2 - and NH 2 CH 2 CH 2 CH 2 -
  • deuterated C 1-6 alkyl-NHC(O)- such as perdeuterated C 1-4 alkyl-NHC(O)-, such as CD 3 -NHC(O)-, CD 3 CD 2 - NHC(O)-, and CD 3 CD 2 CD 2 -NHC(O)-
  • the LIN of the compound of formula (II) represents the structure of the following formula:
  • each group R e is selected from O, N(R g ), C(O), C(O)O, OC(O), S(O), S(O) 2 , S(O) 2 NH , NHS(O) 2 , C(O)N(R g ), N(R g )C(O), or N(R g )C(O)N(R g ), wherein each R g independently represents H or C 1-6 alkyl; each group R is selected from cycloalkylene, arylene, heterocyclylene, heteroarylene, alkynylene, alkenylene or any combination thereof, wherein The cycloalkylene group, the arylene group, the heterocyclylene group and the heteroarylene group are independently of each other optionally further selected from deuterium, an optionally deuterated C 1-6 alkyl group (such as may be deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropy
  • One or more (eg 1-30 ) CH hydrogens of the C 1-30 alkylene group are optionally further replaced by substituents selected from: deuterium, hydroxyl, amino, mercapto, nitro, halogen (such as fluorine, chlorine, bromine or iodine), cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl group, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH -, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), optionally deuterated
  • optionally deuterated C 1-4 alkoxy e.g. methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy , butoxy, sec-butyloxy or tert-butyloxy
  • optionally deuterated C 1-6 alkyl-NH- such as optionally deuterated C 1-3 alkyl-NH-, such as CH 3 NH-, CH 3 CH 2 NH- or CH 3 CH 2 CH 2 NH-
  • NH 2 -C 1-6 alkylene eg NH 2 -C 1-3 alkylene-, eg NH 2 CH 2 -, NH 2 CH 2 CH 2 - and NH 2 CH 2 CH 2 CH 2 -
  • optionally deuterated C 1-6 alkyl-NHC(O)- such as optionally deuterated C 1-4 Alkyl-NHC(O)-, such as CH3 -NHC(O)-, CH3CH2 - NHC(O)-, and CH3CH2CH2 -
  • R a1 , R a2 , R a3 , R a4 , R a5 , R a6 , R a7 and R a8 independently represent H, deuterium, hydroxyl, amino, mercapto, nitro, halogen (such as fluorine, chlorine, bromine or iodine) ), cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH -, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH
  • optionally deuterated C 1-4 alkoxy e.g. methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • optionally deuterated C 1-6 alkyl-NH- such as optionally deuterated C 1-3 alkyl-NH-, such as CH 3 NH-, CH 3 CH 2 NH- or CH 3 CH 2 CH 2 NH-
  • NH 2 -C 1-6 alkylene eg NH 2 -C 1-3 alkylene-, eg NH 2 CH 2 -, NH 2 CH 2 CH 2 - and NH 2 CH 2 CH 2 CH 2 -
  • optionally deuterated C 1-6 alkyl-NHC(O)- such as optionally deuterated C 1-4 alkyl-NHC(O)-,
  • the symbol # indicates the point of attachment to the group U ;
  • n1, n2, n3, n4, m1, m2, m3 are each independently selected from integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • the LIN of the compound of formula (II) represents the structure of the following formula:
  • each R independently represents H or C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl) ;
  • the cycloalkylene group, the arylene group, the heterocyclylene group and the heteroarylene group are independently of each other optionally further selected from deuterium, optionally deuterated C 1-6 alkyl (for example optionally deuterated C 1-4 alkyl such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), optionally deuterated C 3- 6 Cycloalkyl (eg, optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl, or optionally perdeuterated cyclohexyl), hydroxyl, amino, Mercapto, halogen (such as fluorine, chlorine, bromine or iodine), optionally deuterated C 1-6 alkoxy (such as optionally deuterated C 1-4 alkoxy, such as methoxy, CD 3 -O -, eth
  • R a1 , R a2 , R a3 , R a4 , R a5 , R a6 , R a7 and R a8 independently represent H, deuterium, hydroxyl, amino, mercapto, nitro, halogen (such as fluorine, chlorine, bromine or iodine) ), cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH -, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH
  • optionally deuterated C 1-4 alkoxy e.g. methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • optionally deuterated C 1-6 alkyl-NH- such as optionally deuterated C 1-3 alkyl-NH-, such as CH 3 NH-, CH 3 CH 2 NH- or CH 3 CH 2 CH 2 NH-
  • NH 2 -C 1-6 alkylene eg NH 2 -C 1-3 alkylene-, eg NH 2 CH 2 -, NH 2 CH 2 CH 2 - and NH 2 CH 2 CH 2 CH 2 -
  • optionally deuterated C 1-6 alkyl-NHC(O)- such as optionally deuterated C 1-4 alkyl-NHC(O)-,
  • the symbol # indicates the point of attachment to the group U ;
  • n1, n2, n3, n4, m1, m2, m3 are each independently selected from integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • LIN of the compound of formula (II) represents the following group:
  • the piperidinylene and the piperazinylene are independently from each other optionally further selected from deuterium, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkane group, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), optionally deuterated C 3-6 cycloalkyl (such as optionally perdeuterated cyclopropyl, optionally perdeuterated cyclobutyl, optionally perdeuterated cyclopentyl or optionally perdeuterated cyclohexyl), hydroxyl, amino, mercapto, halogen (such as fluorine, chlorine, bromine or iodine), optionally deuterated C 1-6 alkoxy (such as optionally deuterated C 1-4 alkoxy, such as methoxy, CD 3 -O-, ethoxy, propoxy, iso propoxy, but
  • Each R independently represents H or C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl);
  • the symbol # indicates the point of attachment to the group U ;
  • n1, n2, n3, n4, m1, m2, m3 are each independently selected from integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • R of the compound of formula (II) represents the following groups:
  • the compound of formula (II) is also a compound of formula (II-1) or formula (II-2):
  • R 1 , R 2 , R 3 , R 4 , (R b ) n and (R a ) m are as defined above for compounds of formula (II) and embodiments thereof.
  • the compound of formula (II) is also a compound of formula (II-3) or formula (II-4):
  • the compound of formula (II) is also a compound of formula (II-5), formula (II-6), formula (II-7), or formula (II-8):
  • R 1 , R 2 , R 3 , R 4 , (R b ) n and Ra are as defined above for compounds of formula (II) and embodiments thereof.
  • A represents CO, CH2 or CD2 ;
  • R 1 , R 2 , R 3 and R 4 are the same or different and independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), optionally deuterated C 1-6 alkyl (such as optional Deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), optionally deuterated C 1-6 alkoxy (e.g.
  • C 1-4 alkoxy such as methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • halogenated C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH- , CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -);
  • R b n means that the benzene ring is substituted by n R b , and each R b is the same or different and independently represents hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto, nitro , amino, cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl , sec-butyl or tert-butyl), optionally deuterated C 1-6 alkoxy (such as optionally deuterated C 1-4 alkoxy, such as methoxy, CD 3 -O-, ethoxy radical, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as
  • n represents the integer 0, 1, 2, or 3;
  • R a represents the structure of the following formula:
  • U 1 and U 2 are the same or different and each independently represents a bond, N(R d ) or O, wherein R d represents H or optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-6 4 alkyl, such as methyl, CD3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl);
  • R d represents H or optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-6 4 alkyl, such as methyl, CD3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl);
  • R c represents an optionally substituted nitrogen-containing monocyclic heterocyclic group or an optionally substituted nitrogen-containing bridging heterocyclic group
  • W represents hydrogen, an optionally substituted nitrogen-containing monocyclic heterocyclic group, an optionally substituted nitrogen-containing bridging heterocyclic group, an optionally substituted cycloalkyl group, an optionally substituted heteroaryl group, an optionally substituted aryl group, C 2-6 alkenyl (such as vinyl, propenyl or butenyl), C 2-6 alkynyl (such as ethynyl, propynyl or butynyl), leaving group, CHO, COOH, NH 2 , hydroxyl or mercapto; and
  • W represents an optionally substituted nitrogen-containing monocyclic heterocyclic group, an optionally substituted nitrogen-containing bridged heterocyclic group, an optionally substituted cycloalkyl group, an optionally substituted heteroaryl group or an optionally substituted aryl group
  • LIN represents a bond, an optionally substituted methylene group, or an optionally substituted linear or branched C 2-30 alkylene group, wherein the main carbon of the linear or branched C 2-30 alkylene group is One or more (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) groups Re and/or one or Multiple (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) groups R f or one or more (for example 1-10, 1 - any combination of 8 or 1-6, eg 1, 2, 3, 4, 5 or 6) groups R e and R f , said groups R e , R f or groups R e and R The combination of f combines one or more pairs (such
  • each group R e is not directly connected to each other; each group R f is selected from Cycloalkylene, arylene, heterocyclylene, heteroarylene, alkynylene, alkenylene or any combination thereof, wherein the cycloalkylene, the arylene, the heterocycle
  • the radical and the heteroarylene group are independently of each other optionally further selected from deuterium, optionally deuterated C 1-6 alkyl (for example optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), optional deuterated C 3-6 cycloalkyl
  • LIN represents optionally substituted methylene, or optionally substituted A linear or branched C 2-30 alkylene group, wherein the main carbon chain of the linear or branched C 2-30 alkylene group is optionally inserted with one or more (such as 1-10 , 1-8 or 1-6, eg 1, 2, 3, 4, 5 or 6) groups R e and/or one or more (eg 1-10, 1-8 or 1- 6, such as 1, 2, 3, 4, 5 or 6) groups R f or one or more (such as 1-10, 1-8 or 1-6, such as 1, 2, 3, 4, 5 or 6) any combination of groups Re and R f , the group Re , R f or the combination of groups Re and R f will combine one or more pairs of the main carbon chain (for example 1-10 pairs, 1-8 pairs or 1-6 pairs, such as 1, 2, 3, 4, 5 or 6 pairs)
  • optionally deuterated C 1-4 alkyl-NHC(O)- such as CH 3 -NHC(O)-, CH 3 CH 2 -NHC(O)-, and CH 3 CH 2 CH 2 -NHC (O)-
  • optionally deuterated C 1-6 alkyl-C(O)NH- such as optionally deuterated C 1-4 alkyl-C(O)NH-, such as CH 3 -C substituents of (O)NH-, CH3CH2 -C(O)NH-, and CH3CH2CH2 - C(O)NH-
  • cyano or any combination thereof ; or
  • LIN represents an optionally substituted methylene group
  • W represents an optionally substituted nitrogen-containing monocyclic heterocyclic group or an optionally substituted nitrogen-containing bridging heterocyclic group
  • the nitrogen-containing monocyclic heterocyclic group, the nitrogen-containing bridged heterocyclyl group, the nitrogen-containing monocyclic heterocyclyl group, the nitrogen-containing bridged heterocyclyl group, the cycloalkyl group, the heterocyclic group Aryl and said aryl are each independently optionally selected by one or more (for example 1-10, 1-8 or 1-6, for example 1, 2, 3, 4, 5 or 6) Substitution from the following substituents: deuterium, hydroxy, amino, mercapto, nitro, halogen (eg fluorine, chlorine, bromine or iodine), cyano, CHO, COOH, N3 , methanesulfonyloxy, trifluoromethanesulfonate Acyloxy, p-toluenesulfonyloxy, C 1-6 alkyl (for example C 1-4 alkyl, for example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or
  • C 1-4 alkoxy e.g. methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyl Oxygen
  • deuterated C 1-6 alkyl-O- C 1-6 alkyl-NH- (such as C 1-3 alkyl-NH-, such as CH 3 NH-, CH 3 CH 2 NH- or CH 3 CH 2 CH 2 NH-), deuterated C 1-6 alkyl-NH- (for example perdeuterated C 1-3 alkyl-NH-, for example CD 3 NH-, CD 3 CD 2 NH- or CD 3 CD 2 CD 2 NH-), NH 2 -C 1-6 alkylene (eg NH 2 -C 1-3 alkylene-, eg NH 2 CH 2 -, NH 2 CH 2 CH 2 - and NH 2 CH 2 CH 2 CH 2 -), C 1-6 alkyl-NHC(O)- (eg C 1-4 alkyl
  • the present disclosure provides a compound of formula (III) or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph Model:
  • R 1 represents a bond
  • W 1 represents a piperidinylene group
  • LIN represents a methylene group
  • R c represents a piperazinylene group, 2,5-diazabicyclo[2.2.1]heptane Alkylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene
  • R b represents Fluorine
  • n represents the integer 1, 2 or 3
  • U1 and U2 are the same or different and each independently represents a bond, NH or O; or
  • R 1 represents a bond
  • W 1 represents a piperazinylene group
  • LIN represents a methylene group
  • R c represents a piperidinylene group, 2,5-diazabicyclo[2.2.1]heptane Alkylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene
  • R b represents Fluorine
  • n represents an integer of 1, 2 or 3
  • U1 and U2 are the same or different and each independently represents a bond, NH or O.
  • R 1 represents a bond
  • W 1 represents piperidinylene
  • LIN represents methylene
  • R c represents piperazinylene, 2,5-diazabicyclo[2.2.1]heptane Alkylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene
  • R b represents Fluorine
  • n represents an integer 1, 2 or 3
  • U1 and U2 are the same or different and each independently represents a bond, NH or O; or
  • R 1 represents a bond
  • W 1 represents a piperazinylene group
  • LIN represents a methylene group
  • R c represents a piperidinylene group, 2,5-diazabicyclo[2.2.1]heptane Alkylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene
  • R b represents fluorine
  • n represents an integer 1, 2 or 3
  • U1 and U2 are the same or different and each independently represents a bond, NH or O.
  • R 1 represents a bond or -O-CH 2 -CH 2 -
  • W 1 represents piperidinylene
  • LIN represents methylene
  • R c represents piperazinylene, 2,5- Diazabicyclo[2.2.1]heptaneylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.
  • R b represents hydrogen, and U 1 and U 2 are identical or different and independently represent a bond, NH or O; or in formula (IV-3), R 1 represents a bond or -O- CH 2 -CH 2 -, W 1 means piperazinylene, LIN means methylene, R c means piperidinylene, 2,5-diazabicyclo[2.2.1]heptane, 8-aza Heterobicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3.1]nonaneylidene, R b represents hydrogen, and U 1 and U 2 are the same or different and each independently represents a bond, NH or O.
  • R 1 represents a bond or represents -O-CH 2 -CH 2 -
  • W 1 represents piperidinylene
  • LIN represents methylene
  • R c represents piperazinylene, 2,5 -diazabicyclo[2.2.1]heptaneylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3 .1]
  • Nonaneylidene R b represents hydrogen
  • U 1 and U 2 are the same or different and each independently represents a bond, NH or O; or
  • R 1 represents a bond or represents -O-CH 2 -CH 2 -
  • W 1 represents piperazinylene
  • LIN represents methylene
  • R c represents piperidinylene, 2,5 -diazabicyclo[2.2.1]heptaneylidene, 8-azabicyclo[3.2.1]octanylidene or 9-ethyl-3-methyl-3,9-diazabicyclo[3.3 .1]
  • Nonaneylidene R b represents hydrogen
  • U 1 and U 2 are the same or different and each independently represents a bond, NH or O.
  • the compound of formula (III) of the present disclosure or its salt (including pharmaceutically acceptable salt), stereoisomer (including enantiomer), solvate, isotopically enriched analog, prodrug or polymorph can bind target protein, recruit target protein to E3 ubiquitin ligase for ubiquitination labeling and degradation.
  • the compound of formula (III) in the present disclosure can specifically target a specific target protein class or family, and exhibit a wide range of pharmacological activities by degrading/inhibiting various target protein classes or families.
  • specific target proteins include, but are not limited to, the target proteins in Table 3 below:
  • the PBM is a small molecule ligand targeting a specific target protein, including but not limited to, a small molecule ligand targeting EGFR, a small molecule ligand targeting CDK4/6, a small molecule ligand targeting ALK Ligands, small molecule ligands targeting RET, small molecule ligands targeting FAK, small molecule ligands targeting BCR-ABL, small molecule ligands targeting BTK, small molecule ligands targeting AR, Small molecule ligands targeting ER or small molecule ligands targeting BET.
  • a small molecule ligand targeting a specific target protein including but not limited to, a small molecule ligand targeting EGFR, a small molecule ligand targeting CDK4/6, a small molecule ligand targeting ALK Ligands, small molecule ligands targeting RET, small molecule ligands targeting FAK, small molecule ligands targeting BCR-ABL, small molecule ligands targeting
  • the PBM comprises a structure selected from the following formulae:
  • R 2 p1 represents that the benzene ring of the formula (PBM-1) is substituted by p1 R 2 , each R 2 is the same or different and each independently represents halogen or halogenated C 1-6 alkyl;
  • R 3 p2 represents that the quinazoline ring of formula (PBM-1) is substituted by p2 R 3 , each R 3 is the same or different and each independently represents C 1-10 alkyl, deuterated C 1-10 Alkyl, C 1-10 alkoxy, heterocyclyloxy, or -NHC(O)R 4 , wherein R 4 is C 1-10 alkyl or C 2-10 alkenyl, for example R 3 represents methyl , Methoxy, For example
  • p1 represents an integer 1, 2, 3, 4 or 5;
  • p2 represents an integer 1, 2, or 3;
  • R 5 p3 represents that the benzene ring of the formula (PBM-2) is substituted by p3 R 5 , each R 5 is the same or different and each independently represents a C 1-10 alkyl group, a deuterated C 1-10 alkyl group , C 1-10 alkoxy or -NHC(O)R 4 , wherein R 4 is C 1-10 alkyl , deuterated C 1-10 alkyl or C 2-10 alkenyl, for example R 5 represents methyl , methoxy or
  • p3 represents an integer 1, 2, 3 or 4;
  • R 6 p4 represents that the 1H-indole ring of the formula (PBM-2) is substituted by p4 R 6 , each R 6 is the same or different and each independently represents C 1-10 alkyl or deuterated C 1- 10 alkyl;
  • p4 represents an integer 0, 1, 2 or 3;
  • R 7 p5 represents that the benzene ring of the formula (PBM-3) is substituted by p5 R 7 , each R 7 is the same or different and each independently represents halogen, hydroxyl, C 1-6 alkyl, halogenated C 1 -6 alkyl, deuterated C 1-6 alkyl, NO 2 , NH 2 , or cyano,
  • p5 represents the integer 2, 3, 4 or 5;
  • R 8 represents a C 6-10 aryl group, or a heteroaryl group comprising 1 or 2 5- to 7-membered rings and 1-4 heteroatoms selected from N, O and S, wherein the C 6-10 Aryl and the heteroaryl are each optionally substituted by one or more R 4a , and each R 4a is the same or different and each independently is halogen, hydroxyl, cyano, amino, nitro, C alkane Base, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy;
  • R 9 represents C 1-10 alkyl (such as ) or deuterated C 1-10 alkyl
  • R 10 means Wherein (R 5a ) p6 means that the piperidine ring is substituted by p6 R 5a , each R 5a is the same or different and each independently represents deuterium, halogen, hydroxyl, C 1-6 alkyl, halogenated C 1-6 alkane group , deuterated C 1-6 alkyl, C 1-6 alkoxy, deuterated C 1-6 alkoxy, NO 2 , NH 2 , or cyano, p6 represents an integer 1, 2, 3, 4 or 5;
  • R 11 represents that the benzene ring and pyridine ring of the formula (PBM-5) are each optionally substituted by p7 R 11 , each R 11 is the same or different and each independently represents halogen, C 1-6 alkyl , halogenated C 1-6 alkyl, or deuterated C 1-6 alkyl, p7 represents an integer of 0, 1, 2 or 3;
  • Ring A of the formula (PBM-6) represents a C 6-10 aryl group or a heteroaryl group comprising 1 or 2 5- to 7-membered rings and 1-4 heteroatoms selected from N, O and S, so The ring A is optionally substituted by one or more R 6a , and each R 6a is the same or different and is independently deuterium, halogen, hydroxyl, cyano, amino, nitro, C 1-6 alkyl, halo C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, halogenated C 1-6 alkoxy, C 2-6 alkenyl, or C 2-6 alkynyl;
  • Ring B of the formula (PBM-6) represents a C 3-15 cycloalkyl group or a heterocyclic group comprising 1 or 2 3- to 7-membered rings and 1-4 heteroatoms selected from N, O and S, wherein the ring B is optionally substituted by one or more R 7a , and each R 7a is the same or different and is independently deuterium, halogen, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterium Substituted C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy;
  • the ring C of the formula (PBM-6) represents a heteroaryl group comprising 1 or 2 5- to 7-membered rings and 1-4 heteroatoms selected from N, O and S, and the ring C is optionally replaced by One or more R 8a are substituted, and each R 8a is the same or different and is independently deuterium, halogen, hydroxyl, cyano, amino, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy;
  • X 1 of formula (PBM-7) represents N or CR 12 , wherein R 12 is hydrogen or represents a bond, and X 2 represents CH or N;
  • R 13 is hydrogen or represents a bond, wherein when R 13 represents a bond, X 1 represents N or CH, and the ring atom N connected to R 13 is directly connected to R 1 ; or when R 13 is hydrogen, X 1 represents CR 12 , wherein R 12 represents a bond, and the ring atom C connected to R 12 is directly connected to R 1 ;
  • R 14 represents -O-aryl, -O-heteroaryl, -C 1-3 alkylene-NHC(O)-heteroaryl, or -C 1-3 alkylene-C(O)NH- Heteroaryl, said aryl and heteroaryl are each independently optionally substituted by one or more R 9a , and each R 9a is the same or different and each independently is deuterium, halogen, hydroxyl, cyano, amino, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl, C 1-6 alkoxy, or halogenated C 1-6 alkoxy;
  • R 15 represents deuterium, hydrogen, halogen, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl or -NHC(O)R 17 , wherein R 17 is C 1-10 Alkyl or C 2-10 alkenyl, for example R 15 represents hydrogen, methyl, or
  • R 16 represents hydrogen, cyano, or amino
  • X 3 of formula (PBM-8) represents CR 21 or a fragment
  • the symbol ## represents the point of attachment of N adjacent to X 3
  • the symbol ### represents the point of attachment to X 4
  • R represents deuterium, hydrogen, halogen, C 1-6 alkyl, halogenated C 1- 6 alkyl, deuterated C 1-6 alkyl, -C(O)-C 1-6 alkyl, -C(O)-deuterated C 1-6 alkyl or -C(O)NR 22 R 23
  • R 22 and R 23 are the same or different and independently represent hydrogen, C 1-6 alkyl or deuterated C 1-6 alkyl, and R 22 and R 23 are not hydrogen at the same time;
  • X 4 of formula (PBM-8) represents N or CR 24 , wherein R 24 represents hydrogen, deuterium, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • X 5 and X 6 each independently represent CH or N;
  • R 18 represents a bond or an optionally substituted heteroarylene (such as a halogen substituted heteroarylene);
  • R 19 represents hydrogen, C 1-6 alkyl, halogenated C 1-6 alkyl, deuterated C 1-6 alkyl, or optionally substituted C 3-7 cycloalkyl;
  • R 20 and R 25 are the same or different and each independently represents hydrogen, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • R 26 represents hydrogen, halogen, C 1-6 alkyl, halogenated C 1-6 alkyl, or deuterated C 1-6 alkyl;
  • R 27 represents hydrogen, cyano, halogen, C 1-6 alkyl, halogenated C 1-6 alkyl, or deuterated C 1-6 alkyl;
  • R 28 p8 represents that the benzene ring of the formula (PBM-10) is substituted by p8 R 28 , each R 28 is the same or different and each independently represents halogen, C 1-6 alkyl, halogenated C 1-6 Alkyl, or deuterated C 1-6 alkyl;
  • p8 represents an integer 1, 2, 3 or 4;
  • R 29 represents NR 30 R 31 , wherein R 30 and R 31 are the same or different and independently represent hydrogen, C 1-6 alkyl or deuterated C 1-6 alkyl;
  • X 7 , X 8 and X 9 of the formula (PBM-11) are the same or different and independently represent N or CH;
  • R 32 p9 represents that the six-membered ring containing X 8 and X 9 of formula (PBM-11) is optionally substituted by p9 R 32 , each R 32 is the same or different and each independently represents halogen, C 1 -6 alkoxy, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p9 represents an integer 0, 1, 2, 3 or 4;
  • R 33 represents halogen, C 1-6 alkoxy, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • R 34 represents -C(O)NHR 35 , -NHC(O)-R 35 , -S(O) 2 NHR 35 , -S(O) 2 R 35 or -P(O)(R 35 ) 2 , wherein Each R 35 is the same or different and each independently represents C 1-6 alkyl or deuterated C 1-6 alkyl;
  • R 36 p10 represents that the benzene ring of the formula (PBM-12) is optionally substituted by p10 R 36 , each R 36 is the same or different and each independently represents halogen, C 1-6 alkoxy, C 1 -6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p10 represents the integer 0, 1, 2, 3 or 4;
  • R 37 represents that the benzene ring of the formula (PBM-13) is substituted by p11 R 37 , each R 37 is the same or different and each independently represents halogen, C 1-6 alkoxy, C 1-6 alkane Base, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p11 represents an integer 0, 1, 2, 3 or 4;
  • R 38 p12 represents that the benzene ring of the formula (PBM-14) is substituted by p12 R 38 , each R 38 is the same or different and each independently represents halogen, C 1-6 alkoxy, C 1-6 alkane Base, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p12 represents an integer 0, 1, 2, 3 or 4;
  • R 39 p13 represents that the 4-oxo-3,4-dihydroquinazoline ring of the formula (PBM-14) is substituted by p13 R 39 , each R 39 is the same or different and each independently represents a halogen, C 1-6 alkoxy, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p13 represents an integer 1, 2, 3 or 4;
  • R 40 p14 represents that the benzene ring of the formula (PBM-15) is substituted by p14 R 40 , each R 40 is the same or different and each independently represents halogen, C 1-6 alkoxy, C 1-6 alkane Base, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p14 represents an integer 1, 2, 3 or 4;
  • R 41 represents halogen, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • R 42 p15 represents that the quinoline ring of the formula (PBM-16) is substituted by p15 R 42 , each R 42 is the same or different and each independently represents halogen, cyano, C 1-6 alkoxy, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p15 represents the integer 2, 3 or 4;
  • R 43 p16 represents that the benzene ring of the formula (PBM-16) is substituted by p16 R 43 , each R 43 is the same or different and each independently represents halogen, C 1-6 alkoxy, C 1-6 alkane Base, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p16 represents an integer 3 or 4;
  • R 44 p17 represents that the benzene ring, pyrimidine ring and pyridine ring of the formula (PBM-17) are each optionally substituted by p17 R 44 , each R 44 is the same or different and each independently represents halogen, C 1-6 alkane Oxygen, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p17 represents an integer 0, 1, 2, 3 or 4;
  • R 45 , R 46 , R 47 and R 48 represents a bond, and the remaining three are the same or different and independently represent hydrogen, halogen, or hydroxyl, wherein when R 45 , R 46 , R 47 and R 48 When one of them represents a bond, the benzene ring or methylene group in the formula (PBM-18) to which the bond is connected is directly connected to R 1 ;
  • R 49 represents that the 1,2,3,4-tetrahydronaphthalene ring of the formula (PBM-19) is substituted by p18 R 49 , each R 49 is the same or different and each independently represents hydrogen, hydroxyl, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl;
  • p18 represents the integer 0, 1, 2, 3 or 4;
  • R 50 and R 51 represents a bond, and the other represents hydrogen, halogen, C 1-6 alkyl, deuterated C 1-6 alkyl or halogenated C 1-6 alkyl, wherein when R 50 and R When one of 51 represents a bond, the benzene ring in the formula (PBM-19) to which the bond is connected is directly connected to R 1 .
  • PBM represents a small molecule ligand targeting EGFR, including but not limited to representing the following formula (PBM-1-1A), formula (PBM-1-1B), formula (PBM-1-1C) or The structure of formula (PBM-1-1D):
  • R 2 p1 means that the benzene ring of formula (PBM-1-1A), formula (PBM-1-1B), formula (PBM-1-1C) or formula (PBM-1-1D) is covered by p1 R 2 is substituted, each R 2 is the same or different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine) or halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C- , FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 -, or CH 2 ClCH 2- );
  • halogen such as fluorine, chlorine, bromine or iodine
  • halogenated C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C- , FCH 2
  • R 3 p2 represents that the quinazoline ring of formula (PBM-1-1A), formula (PBM-1-1B), formula (PBM-1-1C) or formula (PBM-1-1D) is covered by p2 R 3 is substituted, each R 3 is the same or different and each independently represents a C 1-10 alkyl group (such as a C 1-8 alkyl group, a C 1-6 alkyl group or a C 1-4 alkyl group, such as methyl, ethyl, etc.
  • a C 1-10 alkyl group such as a C 1-8 alkyl group, a C 1-6 alkyl group or a C 1-4 alkyl group, such as methyl, ethyl, etc.
  • propyl isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl), deuterated C 1-10 alkyl (e.g.
  • perdeuterated C 1-8 alkane group perdeuterated C 1-6 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.
  • C 1-10 alkoxy Such as C 1-8 alkoxy, C 1-6 alkoxy or C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyl Oxygen or tert-butyloxy), heterocyclyloxy (wherein heterocyclyl is for example containing one or more, for example 1-4 or 1, 2, 3 or 4, selected from nitrogen, oxygen and sulfur 4- to 20-membered monocyclic or bicyclic heterocyclic group), or -NHC(O)R 4 , wherein R 4 is C 1-10 alkyl (for example, C 1-8 alkyl, C 1- 6 Alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl,
  • p1 represents the integer 1, 2, 3, 4 or 5;
  • p2 represents an integer 1, 2, or 3;
  • R 3 represents heterocyclyl-O-, which is a group containing one or more (for example 1-4 or 1, 2, 3 or 4) selected from nitrogen, oxygen and sulfur 4- to 20-membered (e.g., 4-15, 4-12, 4-10, 4-7, or 4-6) monocyclic or bicyclic heterocyclyl of heteroatoms, including but not limited to nitrogen Heterocyclobutyl, oxetanyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, oxazolidinyl, thiazole Alkyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, azepanyl, diazepanyl (e.g.
  • 1,4-diazepanyl Alkyl-1-yl 1,4-diazepanyl Alkyl-1-yl), azacyclooctyl, diazacyclooctyl, azabicyclo[3.1.1]heptyl, azabicyclo[2.2.1]heptanyl, azabicyclo[3.2.
  • R represents:
  • -NHC(O)-C 2-10 alkenyl for example -NHC(O)-ethenyl, -NHC(O)-propenyl or -NHC(O)-butenyl; or
  • the PBM represents a structure of Formula (PBM-1-1), Formula (PBM-1-2), Formula (PBM-1-3), or Formula (PBM-1-4):
  • PBM represents a small molecule ligand targeting EGFR, including but not limited to representing the following formula (PBM-2-1A), formula (PBM-2-1B), formula (PBM-2-1C) or The structure of formula (PBM-2-1D):
  • R 5 p3 represents that the benzene ring of formula (PBM-2-1A), formula (PBM-2-1B), formula (PBM-2-1C) or formula (PBM-2-1D) is covered by p3 R 5 is substituted, each R 5 is the same or different and each independently represents a C 1-10 alkyl group (such as a C 1-8 alkyl group, a C 1-6 alkyl group or a C 1-4 alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl), deuterated C 1-10 alkyl (e.g.
  • Perdeuterated C 1-6 alkyl or perdeuterated C 1-4 alkyl such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.
  • C 1-10 alkoxy such as C 1-8 alkoxy, C 1-6 alkoxy or C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • R 4 is C 1-10 alkyl (such as C 1-8 alkyl, C 1-6 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl), deuterated C 1-10 alkyl (e.g.
  • perdeuterated C 1-8 alkyl perdeuterated C 1-6 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.
  • C 2-10 Alkenyl such as C 2-6 alkenyl or C 2-4 alkenyl, such as vinyl, propenyl, butenyl or pentenyl
  • R represents methyl, methoxy or
  • p3 represents an integer 1, 2, 3 or 4;
  • R 6 p4 represents the 1H-indole ring of formula (PBM-2-1A), formula (PBM-2-1B), formula (PBM-2-1C) or formula (PBM-2-1D) p4 R 6 substitutions, each R 6 is the same or different and each independently represents a C 1-10 alkyl group (such as a C 1-8 alkyl group, a C 1-6 alkyl group or a C 1-4 alkyl group, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl) or deuterated C 1-10 alkyl (e.g. perdeuterated C 1-8 Alkyl, perdeuterated C 1-6 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.); and
  • p4 represents the integer 0, 1, 2 or 3.
  • the PBM represents the structure of the following formula (PBM-2-1):
  • PBM represents a small molecule ligand targeting EGFR, including but not limited to representing the following formula (PBM-3-1A), formula (PBM-3-1B), formula (PBM-3-1C) or The structure of formula (PBM-3-1D):
  • R 7 represents that the benzene ring of formula (PBM-3-1A), formula (PBM-3-1B), formula (PBM-3-1C) or formula (PBM-3-1D) is covered by p5 R 7 is substituted, each R 7 is the same or different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, C 1-6 alkyl (such as C 1-8 alkyl, C 1-6 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl), halogenated C 1-6 Alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -,
  • perdeuterated C 1-6 alkyl perdeuterated C 1-5 alkane or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.), NO 2 , NH 2 , or cyano,
  • p5 represents the integer 2, 3, 4 or 5;
  • R 8 represents a C 6-10 aryl group, or a heteroaryl group comprising 1 or 2 5- to 7-membered rings and 1-4 heteroatoms selected from N, O and S, wherein the C 6-10 Aryl and said heteroaryl are each optionally substituted by one or more (e.g. 1-6, e.g.
  • R 4a is the same or different and Each independently is halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (such as C 1-8 alkyl, C 1-6 alkyl or C 1 -4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl), halogenated C1-6 alkyl (e.g.
  • halogenated C 1-4 alkyl such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or Perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), or halogenated C 1-6 alkoxy (such as halogenated C 1-4 Alkoxy, eg F 3 CO-, FCH 2 -O-, F 2 CH
  • R represents C 6-10 aryl, such as but not limited to phenyl or naphthyl, and each of phenyl or naphthyl is optionally replaced by one or more (such as 1-6, such as 1, 2, 3, 4, 5 or 6) R 4a substitution as defined above.
  • R represents heteroaryl comprising 1 or 2 5- to 7-membered rings and 1-4 heteroatoms selected from N, O and S.
  • R represents 1 or more (such as 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) independently selected from oxygen, nitrogen and sulfur A heteroatomic 5- to 14-membered monocyclic or bicyclic aromatic ring group.
  • heteroaryl examples include, but are not limited to, furyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl , imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuryl, isobenzofuryl, benzothienyl , indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, benzotriazolyl, benzo[2,1,3]oxa Oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2,3]thiadiazol
  • the PBM represents the structure of the following formula (PBM-3-1):
  • PBM represents a small molecule ligand targeting EGFR, including, but not limited to, a structure representing the following formula (PBM-4):
  • R 9 represents C 1-10 alkyl (such as C 1-8 alkyl, C 1-6 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl) or deuterated C 1-10 alkyl (such as per deuterated C 1-8 alkyl, per deuterated C 1-6 Alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.); and
  • R 10 means Wherein (R 5a ) p6 means that the piperidine ring is substituted by p6 R 5a , each R 5a is the same or different and each independently represents deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, C 1-6 Alkyl (such as C 1-8 alkyl, C 1-6 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl or octyl), halogenated C 1-6 alkyl, deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.), C 1-6 al
  • perdeuterated C 1-6 4 alkoxy such as CD 3 -O-, CD 3 CD 2 -O-, or CD 3 CD 2 CD 2 -O-), NO 2 , NH 2 , or cyano
  • p6 represents an integer 1, 2, 3 , 4 or 5.
  • the PBM represents the structure of the following formula (PBM-4-1) or formula (PBM-4-2):
  • PBM represents a small molecule ligand targeting EGFR, including but not limited to representing the following formula (PBM-5-1A), formula (PBM-5-1B), formula (PBM-5-1C) or The structure of formula (PBM-5-1D):
  • each R 11 is the same or different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1 -5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkane group (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CH
  • the PBM represents the structure of the following formula (PBM-5-1):
  • a PBM represents a small molecule ligand targeting AR, including but not limited to a structure representing the following formula (PBM-6-1A):
  • Ring A of the formula (PBM-6-1A) represents a C 6-10 aryl group or a 5- to 20-membered monocyclic or bicyclic heteroaryl group containing 1-4 heteroatoms selected from N, O and S,
  • the ring A is optionally substituted by t1 (for example 1-6, for example 1, 2, 3, 4, 5 or 6) R 6a , and each R 6a is the same or different and each independently is deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, For example methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (for example halogenated C 1-4 alkyl, For example, F
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy, iso propoxy, butoxy, sec-butyloxy or tert-butyloxy
  • halogenated C 1-6 alkoxy eg halogenated C 1-4 alkoxy, eg F 3 CO-, FCH 2 -O-, F 2 CH-O-, ClCH 2 -O-, Cl 2 CH-O-, CF 3 CF 2 -O-, CF 3 CHF-O-, CHF 2 CF 2 -O-, CHF 2 CHF -O-, CF 3 CH 2 -O- or CH 2 ClCH 2 -O-
  • C 2-6 alkenyl such as vinyl, propenyl or butenyl
  • C 2-6 alkynyl such as acetylene group, propynyl or butynyl
  • Ring B of the formula (PBM-6-1A) represents a C 3-15 cycloalkyl group or a 3 to 20-membered heterocyclic group containing 1-4 heteroatoms selected from N, O and S, wherein the ring B can be optionally substituted by t2 (for example 1-6, for example 1, 2, 3, 4, 5 or 6) R 7a , and each R 7a is the same or different and each independently is deuterium, halogen (for example fluorine, chlorine , bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl , such as methyl, ethyl, propyl, isopropyl, butyl group, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-
  • the ring C of the formula (PBM-6-1A) represents a 5- to 20-membered monocyclic or bicyclic heteroaryl group containing 1-4 heteroatoms selected from N, O and S, and the ring C is optionally Substituted by t3 (for example 1-6, for example 1, 2, 3, 4, 5 or 6) R 8a , and each R 8a is the same or different and each independently is deuterium, halogen (for example fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyl yloxy or tert-butyloxy
  • halogenated C 1-6 alkoxy such as halogenated C 1-4 alkoxy, such as F 3 CO-, FCH 2 -O-, F 2 CH-O -, ClCH 2 -O-, Cl 2 CH-O-, CF 3 CF 2 -O-, CF 3 CHF-O-, CHF 2 CF 2 -O-, CHF 2 CHF-O-, CF 3 CH 2 - O- or CH 2 ClCH 2 -O-);
  • t1 represents an integer 1, 2, 3, 4, 5 or 6;
  • t2 represents the integer 1, 2, 3, 4, 5 or 6;
  • t3 represents an integer 1, 2, 3, 4, 5 or 6.
  • the PBM represents the structure of the following formula (PBM-6-1A-1):
  • R 6a t1 represents that the benzene ring of the formula (PBM-6-1A-1) is optionally substituted by t1 R 6a , each R 6a is the same or different and each independently is deuterium, halogen (such as fluorine, chlorine , bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl radical, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C- , FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy, isopropoxy, butane oxy, sec-butyloxy or tert-butyloxy
  • halogenated C 1-6 alkoxy such as halogenated C 1-4 alkoxy, such as F 3 CO-, FCH 2 -O-, F 2 CH-O-, ClCH 2 -O-, Cl 2 CH-O-, CF 3 CF 2 -O-, CF 3 CHF-O-, CHF 2 CF 2 -O-, CHF 2 CHF-O-, CF 3 CH 2 -O- or CH 2 ClCH 2 -O-
  • C 2-6 alkenyl such as vinyl, propenyl or butenyl
  • C 2-6 alkynyl such as ethynyl, propynyl or butynyl
  • C 2-6 alkenyl such as vinyl, propenyl or butenyl
  • Ring B of the formula (PBM-6-1A-1) represents a C 3-15 cycloalkyl group or a 3 to 20-membered heterocyclic group containing 1-4 heteroatoms selected from N, O and S, wherein the ring B is optionally substituted with t2 R 7a , and each R 7a is the same or different and each independently is deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkane C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -
  • Q 1 represents N or CH
  • R 8a t3 represents the nitrogen-containing heteroaryl group of the formula (PBM-6-1A-1) optionally substituted by t3 R 8a , each R 8a is the same or different and each independently is deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy , sec-butyloxy or tert-butyloxy
  • halogenated C 1-6 alkoxy such as halogenated C 1-4 alkoxy, such as F 3 CO-, FCH 2 -O-, F 2 CH-O-, ClCH 2 -O-, Cl 2 CH-O-, CF 3 CF 2 -O-, CF 3 CHF-O-, CHF 2 CF 2 -O-, CHF 2 CHF-O-, CF 3 CH2 - O- or CH2ClCH2 - O-);
  • t1 represents an integer 1, 2, 3, 4, 5 or 6;
  • t2 represents the integer 1, 2, 3, 4, 5 or 6;
  • t3 represents an integer 1 or 2.
  • Q represents N. In some embodiments, Q represents CH.
  • the PBM represents a structure of the following formula (PBM-6-1), formula (PBM-6-2), or formula (PBM-6-3):
  • PBMs represent small molecule ligands targeting BTK, including but not limited to those representing the following formula (PBM-7-1A), formula (PBM-7-1B) or formula (PBM-7-1C) structure:
  • X2 represents CH or N
  • R 14 represents -O-aryl, -O-heteroaryl, -C 1-3 alkylene-NHC(O)-heteroaryl, or -C 1-3 alkylene-C(O)NH- Heteroaryl, said aryl and heteroaryl are each independently optionally substituted by one or more (eg 1-5, eg 1, 2, 3, 4 or 5) R 9a , and each R 9a
  • R 9a The same or different and each independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (such as halo C 1-4
  • R 15 represents deuterium, hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl radical, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4
  • R 16 represents hydrogen, cyano, or amino.
  • R 14 represents -O-aryl, -O-heteroaryl, -C 1-3 alkylene-NHC(O)-heteroaryl, or -C 1-3 alkylene- C(O)NH-heteroaryl, wherein aryl can be optionally substituted C 6-10 aryl, such as but not limited to phenyl or naphthyl, and heteroaryl can be optionally substituted containing 1 or more 5- to 14-membered monocyclic or bicyclic 5- to 14-membered heteroatoms (eg 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) independently selected from oxygen, nitrogen and sulfur aromatic ring group.
  • aryl can be optionally substituted C 6-10 aryl, such as but not limited to phenyl or naphthyl
  • heteroaryl can be optionally substituted containing 1 or more 5- to 14-membered monocyclic or bicyclic 5- to 14-membered heteroatoms (eg 1 to 6, or 1 to 5, or
  • R 14 represents -O-phenyl or -O-naphthyl, phenyl or naphthyl is optionally replaced by one or more (for example 1-5, for example 1, 2, 3, 4 or 5)
  • R 9a is substituted, and each R 9a is the same or different and is independently deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) , halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-
  • perdeuterated C 1-6 alkyl perdeuterated C 1-6 alkyl, perdeuterated C 1-6 alkyl, per Deuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.
  • C 1-6 alkoxy such as C 1 -4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • halogenated C1-6 alkoxy group such as halogenated C 1-4 alkoxy, such as F 3 CO-, FCH 2 -O-, F 2 CH-O-, ClCH 2 -O-, Cl 2 CH-O-, CF 3 CF 2 - O-, CF 3 CHF-O-, CHF 2 CF 2 -O-, CHF 2 CHF-O-, CF 3 CH 2 -O- or CH 2 ClCH 2 -O-
  • R 14 represents -O-heteroaryl, -C 1-3 alkylene-NHC(O)-heteroaryl, or -C 1-3 alkylene-C(O)NH -heteroaryl
  • heteroaryl is optionally substituted by one or more (for example 1-5, for example 1, 2, 3, 4 or 5) R 9a
  • each R 9a is the same or different and each independently is deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl , such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl , such
  • the PBM represents the structure of the following formula (PBM-7-1) or formula (PBM-7-2):
  • PBM represents a small molecule ligand targeting CDK4/6, including but not limited to representing the following formula (PBM-8-1A), formula (PBM-8-1B), formula (PBM-8-1C ) or the structure of formula (PBM-8-1D):
  • R 21 represents deuterium, hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl radical, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4
  • perdeuterated C 1-6 alkyl perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.), and R 22 and R 23 are not at the same time hydrogen;
  • X 4 represents N or CR 24 , wherein R 24 represents hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as perdeuterium Substituted C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.) or halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF
  • X 5 and X 6 each independently represent CH or N;
  • Ring D represents an optionally substituted heteroarylene (eg, a halogen-substituted heteroarylene);
  • R 19 represents hydrogen, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl , sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), deuterated C 1-6 alkane (such as perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -
  • R 20 and R 25 are the same or different and independently represent hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.) or halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF
  • ring D represents optionally substituted heteroarylene, for example optionally substituted containing 1 or more (eg 1 to 6, or 1 to 5, or 1 to 4, or 1 to 3) 5- to 20-membered monocyclic or bicyclic heteroarylene of heteroatoms independently selected from oxygen, nitrogen and sulfur.
  • heteroarylene examples include, but are not limited to, furylylene, oxazolylene, isoxazolylene, oxadiazolylidene, thienylene, thiazolylylene, isothiazolylene, thiadiazolylylene, Pyrrolene, imidazolyl, pyrazolylene, triazolylene, pyridinylene, pyrimidinylene, pyridazinylene, pyrazinylene, indolylene, isoindolylene, benzo Furyl, isobenzofuryl, benzothienyl, indazolyl, benzimidazolylene, benzoxazolylene, benzoisoxazolylene, benzothiazolyl, phenylene Aisothiazolyl, benzotriazolylene, benzo[2,1,3]oxadiazolyl, benzo[2,1,3]thiadiazolyl, benzo[1,2, 3] Thiadiazolyl, quinolin
  • Heteroarylene is optionally substituted with one or more (eg 1-5, eg 1, 2, 3, 4 or 5) substituents selected from the group consisting of halogen (eg fluorine, chlorine, bromine or iodine) , hydroxy, cyano, amino, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl , butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH -, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2
  • perdeuterated C 1-6 alkyl perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 ⁇ , CD 3 CD 2 CD 2 - etc.
  • C 1-6 alkoxy e.g. C 1-4 alkoxy, e.g.
  • halogenated C 1-6 alkoxy such as halogenated C 1-4 alkoxy, such as F 3 CO-, FCH 2 -O-, F 2 CH-O-, ClCH 2 -O-, Cl 2 CH-O-, CF 3 CF 2 -O-, CF 3 CHF-O-, CHF 2 CF 2 -O-, CHF 2 CHF-O-, CF 3 CH 2 -O- or CH2ClCH2 - O-).
  • the PBM represents a structure of the following formula (PBM-8-1), formula (PBM-8-2), or formula (PBM-8-3):
  • PBM represents a small molecule ligand targeting ALK, including but not limited to representing the following formula (PBM-9-1A), formula (PBM-9-1B), formula (PBM-9-1C) or The structure of formula (PBM-9-1D):
  • R 26 represents hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C -, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 -, or CH 2 ClCH 2 -), or deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or per deuterated C 1-4 alky
  • R 27 represents hydrogen, cyano, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (for example halogenated C 1-4 alkyl, for example F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), or deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or per deuterated C 1-4 al
  • the PBM represents the structure of the following formula (PBM-9-1):
  • PBM represents a small molecule ligand targeting ALK, including but not limited to representing a structure of the following formula (PBM-10):
  • R 28 p8 represents that the benzene ring of the formula (PBM-10) is substituted by p8 R 28 , each R 28 is the same or different and each independently represents a halogen (such as fluorine, chlorine, bromine or iodine), C 1- 6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl , pentyl or hexyl), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), or de
  • p8 represents the integer 1, 2, 3 or 4;
  • R 29 represents NR 30 R 31 , wherein R 30 and R 31 are the same or different and independently represent hydrogen, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 Alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) or deuterated C 1-6 alkyl (such as perdeuterated C 1-6 6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.).
  • C 1-6 alkyl such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 Alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or
  • the PBM represents the structure of the following formula (PBM-10-1):
  • the PBM represents a structure of Formula (PBM-11-1A), Formula (PBM-11-1B), or Formula (PBM-11-1C):
  • X 7 , X 8 and X 9 are the same or different and independently represent N or CH;
  • R 32 p9 represents that the six-membered ring containing X 8 and X 9 is optionally substituted by p9 R 32 , each R 32 is the same or different and each independently represents a halogen (such as fluorine, chlorine, bromine or iodine) , C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy base ) , C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, secondary butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or per deuterated C 1-4
  • p9 represents an integer 0, 1, 2, 3 or 4;
  • R 33 represents halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkoxy, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkane group, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 Alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.) or halogenated C 1-6 alkane group (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CH
  • R 34 represents -C(O)NHR 35 , -NHC(O)-R 35 , -S(O) 2 NHR 35 , -S(O) 2 R 35 or -P(O)(R 35 ) 2 , wherein Each R 35 is the same or different and each independently represents a C 1-6 alkyl group (such as a C 1-6 alkyl group, a C 1-5 alkyl group or a C 1-4 alkyl group, such as a methyl group, an ethyl group, a propyl group , isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) or deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkane group or perdeuterated C 1-4 alkyl group, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.).
  • a PBM represents a small molecule ligand targeting ALK, including but not limited to a ligand representing the following formula (PBM-11-1D), formula (PBM-11-1E) or formula (PBM-11-1F) structure:
  • X 8 and X 9 are the same or different and each independently represents N or CH;
  • R 32 p9 means that the six-membered ring containing X 8 and X 9 is optionally substituted by p9 R 32 , each R 32 is the same or different and each independently represents a halogen (such as fluorine, chlorine, bromine or iodine) , C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy base ) , C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, secondary butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or per deuterated C 1-4
  • p9 represents the integer 0, 1, 2, 3 or 4;
  • R 34 represents -C(O)NHR 35 , -NHC(O)-R 35 , -S(O) 2 NHR 35 , -S(O) 2 R 35 or -P(O)(R 35 ) 2 , wherein Each R 35 is the same or different and each independently represents a C 1-6 alkyl group (such as a C 1-6 alkyl group, a C 1-5 alkyl group or a C 1-4 alkyl group, such as a methyl group, an ethyl group, a propyl group , isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) or deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkane group or perdeuterated C 1-4 alkyl group, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.).
  • a PBM represents a small molecule ligand targeting ALK, including but not limited to a structure representing the following formula (PBM-11-1) or formula (PBM-11-2):
  • PBMs represent small molecule ligands targeting FAK, including but not limited to those representing the following formula (PBM-11-1G), formula (PBM-11-1H) or formula (PBM-11-1I) structure:
  • X 8 and X 9 are the same or different and each independently represents N or CH;
  • R 32 p9 means that the six-membered ring containing X 8 and X 9 is optionally substituted by p9 R 32 , each R 32 is the same or different and each independently represents a halogen (such as fluorine, chlorine, bromine or iodine) , C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy base ) , C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, secondary butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or per deuterated C 1-4
  • p9 represents the integer 0, 1, 2, 3 or 4;
  • R 34 represents -C(O)NHR 35 , -NHC(O)-R 35 , -S(O) 2 NHR 35 , -S(O) 2 R 35 or -P(O)(R 35 ) 2 , wherein Each R 35 is the same or different and each independently represents a C 1-6 alkyl group (such as a C 1-6 alkyl group, a C 1-5 alkyl group or a C 1-4 alkyl group, such as a methyl group, an ethyl group, a propyl group , isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) or deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkane group or perdeuterated C 1-4 alkyl group, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.).
  • PBMs represent small molecule ligands targeting FAK, including but not limited to those representing the following formula (PBM-11-1G), formula (PBM-11-1H) or formula (PBM-11-1I) structure:
  • PBM represents a small molecule ligand targeting RET, including, but not limited to, those representing the following formula (PBM-11-1J), formula (PBM-11-1K) or formula (PBM-11-1L) structure:
  • X 8 and X 9 are the same or different and each independently represents N or CH;
  • R 32 p9 means that the six-membered ring containing X 8 and X 9 is optionally substituted by p9 R 32 , each R 32 is the same or different and each independently represents a halogen (such as fluorine, chlorine, bromine or iodine) , C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy base ) , C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, secondary butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or per deuterated C 1-4
  • p9 represents the integer 0, 1, 2, 3 or 4;
  • R 34 represents -C(O)NHR 35 , -NHC(O)-R 35 , -S(O) 2 NHR 35 , -S(O) 2 R 35 or -P(O)(R 35 ) 2 , wherein Each R 35 is the same or different and each independently represents a C 1-6 alkyl group (such as a C 1-6 alkyl group, a C 1-5 alkyl group or a C 1-4 alkyl group, such as a methyl group, an ethyl group, a propyl group , isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl) or deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkane group or perdeuterated C 1-4 alkyl group, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.).
  • a PBM represents a small molecule ligand targeting RET, including, but not limited to, a structure representing the following formula (PBM-11-4) or formula (PBM-11-5):
  • PBM represents a small molecule ligand targeting RET, including but not limited to representing the following formula (PBM-12-1A), formula (PBM-12-1B), formula (PBM-12-1C), The structure of formula (PBM-12-1D) or formula (PBM-12-1E):
  • each R 36 is the same or different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkoxy (such as C 1- 4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), C 1-6 alkyl (such as C 1 -6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), Deuterated C 1-6 alkyl (such as perdeuterated
  • p10 represents the integer 0, 1, 2, 3 or 4;
  • a PBM represents a small molecule ligand targeting RET, including, but not limited to, a structure representing the following formula (PBM-12-1):
  • PBM represents a small molecule ligand targeting BET, including, but not limited to, a structure representing the following formula (PBM-13):
  • R 37 p11 represents that the benzene ring of the formula (PBM-13) is substituted by p11 R 37 , each R 37 is the same or different and each independently represents a halogen (such as fluorine, chlorine, bromine or iodine), C 1- 6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or per deuterated C 1-4 alkyl, such as CD 3 ,
  • p11 represents the integer 0, 1, 2, 3 or 4.
  • PBM represents a small molecule ligand targeting BET, including, but not limited to, a structure representing the following formula (PBM-13):
  • PBM represents a small molecule ligand targeting BET, including but not limited to representing the following formula (PBM-14-1A), formula (PBM-14-1B), formula (PBM-14-1C), The structure of formula (PBM-14-1D) or formula (PBM-14-1E):
  • each R 38 is the same or different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkoxy (such as C 1-4 alkoxy group, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), C 1-6 alkyl (such as C 1-6 alk C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl
  • p12 represents an integer 0, 1, 2, 3 or 4;
  • R 39 p13 means formula (PBM-14-1A), formula (PBM-14-1B), formula (PBM-14-1C), formula (PBM-14-1D) or formula (PBM-14-1E)
  • the 4-oxo-3,4-dihydroquinazoline ring is substituted by p13 R 39 , each R 39 is the same or different and each independently represents a halogen (such as fluorine, chlorine, bromine or iodine), C 1 -6 alkoxy (for example C 1-4 alkoxy, for example methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C
  • p13 represents the integer 1, 2, 3 or 4.
  • a PBM represents a small molecule ligand targeting BET, including but not limited to a structure representing the following formula (PBM-14-1):
  • a PBM represents a small molecule ligand that targets BCR-ABL, including but not limited to structures representing the following formula (PBM-15-1A) or formula (PBM-15-1B):
  • R 40 p14 represents that the benzene ring of formula (PBM-15-1A) or formula (PBM-15-1B) is substituted by p14 R 40 , each R 40 is the same or different and each independently represents a halogen (such as fluorine , chlorine, bromine or iodine), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyl Oxygen or tert-butyloxy), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, iso propyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as per deuterated C 1-6 alkyl, per deuterated C 1-5 alkyl or Perdeuter
  • p14 represents the integer 1, 2, 3 or 4;
  • R 41 represents halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl , propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl, perdeuterated C 1 -5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.) or halogenated C 1-6 alkyl (such as halogenated C 1- 4Alkyl , such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2
  • a PBM represents a small molecule ligand targeting BCR-ABL, including but not limited to a structure representing the following formula (PBM-15-1):
  • PBM represents a small molecule ligand targeting BCR-ABL, including but not limited to representing the following formula (PBM-16-1A), formula (PBM-16-1B), formula (PBM-16-1C ) or the structure of formula (PBM-16-1D):
  • R 42 p15 represents that the quinoline ring of formula (PBM-16-1A), formula (PBM-16-1B), formula (PBM-16-1C) or formula (PBM-16-1D) is covered by p15 R 42 is substituted, each R 42 is the same or different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine), cyano, C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), C 1-6 alkyl (such as C 1-6 alkyl, C 1- 5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl,
  • halogenated C 1-6 alkyl eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 - , CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -);
  • p15 represents the integer 2, 3 or 4;
  • R 43 p16 means that the benzene ring of formula (PBM-16-1A), formula (PBM-16-1B), formula (PBM-16-1C) or formula (PBM-16-1D) is covered by p16 R 43 is substituted, each R 43 is the same or different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy group, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as perdeuterium Substituted C 1-6
  • p16 represents the integer 3 or 4.
  • a PBM represents a small molecule ligand targeting BCR-ABL, including but not limited to a structure representing the following formula (PBM-16-1):
  • PBM represents a small molecule ligand targeting BCR-ABL, including but not limited to representing the following formula (PBM-17-1A), formula (PBM-17-1B), formula (PBM-17-1C ), the structure of formula (PBM-17-1D) or formula (PBM-17-1E):
  • R 44 p17 means formula (PBM-17-1A), formula (PBM-17-1B), formula (PBM-17-1C), formula (PBM-17-1D) or formula (PBM-17-1E)
  • the benzene ring, pyrimidine ring and pyridine ring are each optionally substituted by p17 R 44 , each R 44 is the same or different and each independently represents halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkoxy (e.g.
  • C 1-4 alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • C 1-6 alkoxy such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl , ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl group or hexyl
  • deuterated C 1-6 alkyl such as perdeuterated C 1-6 alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.
  • halogenated C 1-6 alkyl eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3
  • p17 represents the integer 0, 1, 2, 3 or 4.
  • a PBM represents a small molecule ligand targeting BCR-ABL, including but not limited to a structure representing the following formula (PBM-17-1):
  • PBM represents a small molecule ligand targeting ER, including but not limited to representing the following formula (PBM-18-1A), formula (PBM-18-1B), formula (PBM-18-1C) or The structure of formula (PBM-18-1D):
  • R 45 , R 46 , R 47 and R 48 are the same or different and each independently represents hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), or hydroxyl; and
  • PBM represents a small molecule ligand targeting ER, including but not limited to representing the following formula (PBM-18-1), formula (PBM-18-2), formula (PBM-18-3), The structure of formula (PBM-18-4), formula (PBM-18-5) or formula (PBM-18-6):
  • a PBM represents a small molecule ligand targeting ER, including but not limited to a structure representing the following formula (PBM-19-1A) or formula (PBM-19-1B):
  • R 49 represents that the 1,2,3,4-tetrahydronaphthalene ring of formula (PBM-19-1A) or formula (PBM-19-1B) is replaced by p18 R 49 , each R 49 is the same or different and Each independently represents hydrogen, hydroxyl, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (e.g.
  • perdeuterated C 1-6 alkyl Perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.
  • halogenated C 1-6 alkyl such as Halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -);
  • p18 represents the integer 0, 1, 2, 3 or 4;
  • R 50 and R 51 each independently represent hydrogen, halogen (such as fluorine, chlorine, bromine or iodine), C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkane group, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 Alkyl, perdeuterated C 1-5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -, etc.) or halogenated C 1-6 alkane group (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CH
  • PBM represents a small molecule ligand targeting ER, including but not limited to representing a structure of the following formula (PBM-19-1):
  • said R 1 represents a structure of the following formula:
  • Bond, -O-, C 1-6 alkylene optionally substituted by a substituent selected from halogen and C 1-3 alkyl e.g., methylene, ethylene, propylene, isopropylidene , butylene, tert-butylene, pentylene, and hexylene
  • -N(R 1a )-R 2a -*** eg -N(CH 3 )-CH 2 CH 2 -***, - NH-CH 2 CH 2 -***
  • -OR 2a -*** eg -O-(CH 2 ) 3 -***, -O-CH 2 -*** and -O-(CH 2 ) 2 -***
  • -C(O)NH-R 2a -***(eg -C(O)NH-(CH 2 ) 2 -***, -C(O)NH-(CH 2 ) 3 -***, -C(O)NH-CH CH-CH 2 -***
  • Phenylene or naphthylene wherein each of said phenylene or naphthylene is independently optionally substituted by one or more R 3a , and each R 3a is the same or different and each independently is halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, cyano, amino, nitro, C 1-6 alkyl (such as C 1-6 alkyl, C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C -, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-
  • the W 1 is t connected rings W 2 represented by the following structural formula:
  • each ring W 2 is the same or different and each independently is the following groups:
  • Monocyclic C 3-10 heterocyclylenes containing one nitrogen atom and optionally heteroatoms selected from nitrogen, oxygen and sulfur for example represent the following groups: piperidinylene, piperazinylene, morpholine group, azetidinyl group, pyrrolidinyl group, imidazolidinyl group, pyrazolidinyl group, oxazolidinyl group, thiazolidinyl group, thiomorpholinyl group, azepanylidene group, Diazepanylidene, azacyclooctylene or diazepanylidene; or
  • a C5-20 bridged heterocyclylene group containing a nitrogen atom and optionally a heteroatom selected from nitrogen, oxygen and sulfur for example represents the following groups: azabicyclo[3.1.1]heptaneylidene, nitrogen Heterobicyclo[2.2.1]heptane, azabicyclo[3.2.1]octane, azabicyclo[2.2.2]octane, diazabicyclo[3.1.1]heptane group, diazabicyclo[2.2.1]heptaneylidene, diazabicyclo[3.2.1]octaneylidene or diazabicyclo[2.2.2]octaneylidene, for example representing the following groups:
  • Cycloalkylene for example, represents the following groups: cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cyclohexenylene, cycloheptylene , cyclooctylene, decahydronaphthylene, octahydropentalene, octahydro-1H-indenylene, C 5-15 spirocyclylene, adamantyl, noradamantyl , bornylidene, bicyclo[2.2.1]heptaneylidene, or bicyclo[2.2.1]heptenylidene;
  • the monocyclic C 3-10 heterocyclylene, the C 5-20 bridged heterocyclylene and the C 3-15 cycloalkylene are each independently optionally selected from one or more of the following Substituent substitution: deuterium, hydroxyl, amino, mercapto, nitro, halogen (such as fluorine, chlorine, bromine or iodine), cyano, optionally deuterated C 1-6 alkyl, halogenated C 1-6 alkane group (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), optionally deuterated C 3-6 cycloalkyl (such as optionally deuterated cyclopropyl, cyclobutyl, cyclopentyl or
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • optionally deuterated C 1-6 alkyl-NH- NH 2 -C 1-6 alkylene
  • optionally deuterated C 1-6 alkyl -NHC(O)- optionally deuterated C 1-6 alkyl-C(O)NH- or any combination thereof
  • C 1-4 alkoxy e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • optionally deuterated C 1-6 alkyl-NH- NH 2 -C 1-6 alkylene
  • optionally deuterated C 1-6 alkyl -NHC(O)- optionally deuterated C 1-6 alkyl-C(O)NH- or any combination thereof
  • t represents the integer 1 or 2.
  • said W represents the following groups:
  • the group is optionally further selected from one or more groups selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), cyano, amino, C 1-6 alkyl (such as C 1-6 alkyl , C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1 -6 alkyl (e.g.
  • halogenated C 1-4 alkyl such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl, perdeuterated C 1-6 5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC1-6alkoxy (e.g.
  • haloC1 -4 alkoxy such as F 3 CO-, FCH 2 -O-, F 2 CH-O-, ClCH 2 -O-, Cl 2 CH-O-, CF 3 CF 2 -O-, CF 3 CHF- O-, CHF 2 CF 2 -O-, CHF 2 CHF-O-, CF 3 CH 2 -O- or CH 2 ClCH 2 -O-), deuterated C 1-6 alkoxy or any combination thereof base substitution.
  • the R 1 -W 1 represents the following groups:
  • the group is optionally further selected from one or more groups selected from deuterium, halogen (such as fluorine, chlorine, bromine or iodine), cyano, amino, C 1-6 alkyl (such as C 1-6 alkyl , C 1-5 alkyl or C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl or hexyl), halogenated C 1 -6 alkyl (e.g.
  • halogenated C 1-4 alkyl such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), deuterated C 1-6 alkyl (such as perdeuterated C 1-6 alkyl, perdeuterated C 1-6 5 alkyl or perdeuterated C 1-4 alkyl, such as CD 3 , CD 3 CD 2 -, CD 3 CD 2 CD 2 -), C 1-6 alkoxy (such as C 1-4 alkoxy, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), haloC1-6alkoxy (e.g.
  • haloC1 -4 alkoxy such as F 3 CO-, FCH 2 -O-, F 2 CH-O-, ClCH 2 -O-, Cl 2 CH-O-, CF 3 CF 2 -O-, CF 3 CHF- O-, CHF 2 CF 2 -O-, CHF 2 CHF-O-, CF 3 CH 2 -O- or CH 2 ClCH 2 -O-), deuterated C 1-6 alkoxy or any combination thereof base substitution.
  • the ULM represents the following formula (ULM-1), formula (ULM-2), formula (ULM-3), formula (ULM-4), formula (ULM-5), formula (ULM- 6), the structure of formula (ULM-7), formula (ULM-8), formula (ULM-9), or formula (ULM-10):
  • A represents CO, CH2 or CD2 ;
  • R 1 , R 2 , R 3 and R 4 are the same or different and independently represent hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), optionally deuterated C 1-6 alkyl (such as optional Deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), optionally deuterated C 1-6 alkoxy (e.g.
  • C 1-4 alkoxy such as methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy
  • halogenated C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH- , CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -);
  • R b n means that the benzene ring is optionally substituted by n R b , each R b is the same or different and each independently represents hydrogen, deuterium, halogen (such as fluorine, chlorine, bromine or iodine), hydroxyl, mercapto , nitro, amino, cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl , butyl, sec-butyl or tert-butyl), optionally deuterated C 1-6 alkoxy (such as optionally deuterated C 1-4 alkoxy, such as methoxy, CD 3 -O- , ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl,
  • n represents the integer 0, 1, 2 or 3;
  • U 1 and U 2 are the same or different and each independently represents a bond, N(R d ) or O, wherein R d represents H or optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-6 4 alkyl, such as methyl, CD3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl);
  • R d represents H or optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-6 4 alkyl, such as methyl, CD3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl);
  • R c represents an optionally substituted monocyclic C 3-10 heterocyclylene containing a nitrogen atom and optionally a heteroatom selected from nitrogen, oxygen and sulfur, for example representing the following groups: piperidinylene, Piperazinyl, morpholinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, thiazolidinyl, thiomorpholinyl, Azepanylidene, diazepanylidene, azacyclooctylene or diazepanylidene; or
  • R c represents an optionally substituted C5-20 bridged heterocyclylene containing a nitrogen atom and optionally a heteroatom selected from nitrogen, oxygen and sulfur, for example representing the following group: azabicyclo[3.1.1 ]heptane, azabicyclo[2.2.1]heptane, azabicyclo[3.2.1]octane, azabicyclo[2.2.2]octane, diazabicyclo[ 3.1.1]heptaneylidene, diazabicyclo[2.2.1]heptaneylidene, diazabicyclo[3.2.1]octanylidene or diazabicyclo[2.2.2]octanylidene , for example representing the following groups:
  • the monocyclic C 3-10 heterocyclylene and the C 5-20 bridging heterocyclylene are each independently optionally further substituted by one or more substituents selected from the group consisting of deuterium, hydroxyl, amino , mercapto, nitro, halogen (such as fluorine, chlorine, bromine or iodine), cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 -, or
  • optionally deuterated C 1-4 alkoxy such as methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert Butyloxy
  • optionally deuterated C 1-6 alkyl-NH- NH 2 -C 1-6 alkylene
  • optionally deuterated C 1-6 alkyl-NHC(O)- optionally deuterated C 1-6 alkyl-C(O)NH- or any combination thereof.
  • said R c represents the following groups:
  • the ULM represents the following formula (ULM-11), formula (ULM-12), formula (ULM-13), formula (ULM-14), formula (ULM-15), formula (ULM- 16), the structure of formula (ULM-17), formula (ULM-18), formula (ULM-19), formula (ULM-20), formula (ULM-21) or formula (ULM-22):
  • the ULM represents a structure of the formula:
  • the LIN represents the structure of the formula:
  • each group R e is selected from O, N(R g ), C(O), C(O)O, OC(O), S(O), S(O) 2 , S(O) 2 NH , NHS(O) 2 , C(O)N(R g ), N(R g )C(O), or N(R g )C(O)N(R g ), wherein each R g independently represents H or C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl); each group R is selected from Cycloalkylene, arylene, heterocyclylene, heteroarylene, alkynylene, alkenylene or any combination thereof, wherein the cycloalkylene, the arylene, the heterocycle
  • the radical and the heteroarylene group are independently of each other optionally further selected from deuterium, optionally deuterated C
  • the hydrogen of one or more CH of the C 1-30 alkylene group is optionally further replaced by a substituent selected from: deuterium, hydroxyl, amino, mercapto, nitro, halogen (such as fluorine, chlorine, bromine or iodine), cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl group, sec-butyl or tert-butyl), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C- , FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), optionally deuterated C 3-6 cycl
  • R a1 , R a2 , R a3 , R a4 , R a5 , R a6 , R a7 and R a8 independently represent H, deuterium, hydroxyl, amino, mercapto, nitro, halogen, cyano, optional deuterated C 1-6 alkyl (e.g.
  • C 1-4 alkyl such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl
  • halogen Substituted C 1-6 alkyl such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -
  • optionally deuterated C 3-6 cycloalkyl such as optionally deuterated cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl
  • optionally deuterated C 1-6 alkoxy optionally deuterated C 1-6 alkyl-NH-, NH 2 -C 1-6 alkylene , optional deuterated
  • the symbol # indicates the point of attachment to the group U ;
  • n1, n2, n3, n4, m1, m2, m3 are each independently selected from integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • the LIN represents the structure of the formula:
  • each R independently represents H or C 1-6 alkyl
  • the cycloalkylene group, the arylene group, the heterocyclylene group and the heteroarylene group are independently of each other optionally further selected from deuterium, optionally deuterated C 1-6 alkyl (for example optionally deuterated C 1-4 alkyl such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), optionally deuterated C 3- 6 Cycloalkyl (such as optionally deuterated cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), hydroxyl, amino, mercapto, halogen (such as fluorine, chlorine, bromine or iodine), optionally deuterated C 1-6 alkoxy, optionally deuterated C 1-6 alkyl-NH-, halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -
  • R a1 , R a2 , R a3 , R a4 , R a5 , R a6 , R a7 and R a8 independently represent H, deuterium, hydroxyl, amino, mercapto, nitro, halogen (such as fluorine, chlorine, bromine or iodine) ), cyano, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), halogenated C 1-6 alkyl (eg halogenated C 1-4 alkyl, eg F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH -, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH
  • the symbol # indicates the point of attachment to the group U ;
  • n1, n2, n3, n4, m1, m2, m3 are each independently selected from integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • the LIN represents the following groups:
  • the piperidinylene and the piperazinylene are independently from each other optionally further selected from deuterium, optionally deuterated C 1-6 alkyl (such as optionally deuterated C 1-4 alkane such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl, sec-butyl or tert-butyl), optionally deuterated C 3-6 cycloalkyl (such as optionally deuterated cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl), hydroxyl, amino, mercapto, halogen (such as fluorine, chlorine, bromine or iodine), optionally deuterated C 1-6 alkoxy (such as optional Deuterated C 1-4 alkoxy, such as methoxy, CD 3 -O-, ethoxy, propoxy, isopropoxy, butoxy, sec-butyloxy or tert-butyloxy ), optionally deuterated
  • Each R independently represents H or C 1-6 alkyl
  • the symbol # indicates the point of attachment to the group U ;
  • n1, n2, n3, n4, m1, m2, m3 are each independently selected from integers 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
  • the -W 1 -LIN-U 2 -R c -U 1 - represents the following groups:
  • the group is optionally further selected from deuterium, Halogen (such as fluorine, chlorine, bromine or iodine), cyano, amino, C 1-6 alkyl (such as C 1-4 alkyl, such as methyl, CD 3 , ethyl, propyl, isopropyl, butyl group, sec-butyl or tert-butyl), halogenated C 1-6 alkyl (such as halogenated C 1-4 alkyl, such as F 3 C-, FCH 2 -, F 2 CH-, ClCH 2 -, Cl 2 CH-, CF 3 CF 2 -, CF 3 CHF-, CHF 2 CF 2 -, CHF 2 CHF-, CF 3 CH 2 - or CH 2 ClCH 2 -), deuterated C 1-6 alkyl (eg per Deuterated C 1-4 alkyl, such as perdeuterated methyl (CD 3 ), perdeuterated ethyl, perdeuterated propyl,
  • the compound of formula (III) is also composed of the following formula (III-1), formula (III-2), formula (III-3), formula (III-4), formula (III-5), formula (III-6), formula (III-7), formula (III-8), formula (III-9), formula (III-10), formula (III-11), formula (III-12), formula ( III-13), formula (III-14), formula (III-15), formula (III-16), formula (III-17), formula (III-18), formula (III-19), formula (III -20), formula (III-21), formula (III-22), formula (III-23) or the structural representation of formula (III-24):
  • ULM represents the structure of the following formula (ULM):
  • W 1 represents optionally substituted piperidinylene
  • R c represents optionally substituted piperidinylene
  • U 1 represents a bond
  • A, R 1 , R 2 , R 3 , R 4 , (R b ) n , U 2 , LIN, R 1 , (R 6a ) t1 , ring B, (R 7a ) t2 , (R 8a ) t3 , Q 1 are as defined above in the compound of formula (III) and its subembodiments, wherein W 1 and the substituents of the piperidinylene represented by R c are each independently as defined herein.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/CN2022/126516 2021-10-22 2022-10-20 Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用 Ceased WO2023066350A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP22882955.2A EP4421071A4 (en) 2021-10-22 2022-10-20 E3 CRBN LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF A LIGAND COMPOUND, AND THEIR USES
AU2022370021A AU2022370021B2 (en) 2021-10-22 2022-10-20 Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
JP2024524582A JP2024539269A (ja) 2021-10-22 2022-10-20 Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
CA3235512A CA3235512A1 (en) 2021-10-22 2022-10-20 Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications
KR1020247016562A KR20240110576A (ko) 2021-10-22 2022-10-20 Crbn e3 리가제 리간드 화합물, 리간드 화합물에 기초하여 개발된 단백질 분해제 및 이들의 응용
US18/703,316 US20250243210A1 (en) 2021-10-22 2022-10-20 Crbn e3 ligase ligand compound, protein degrader developed based thereon and their applications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111231963.9 2021-10-22
CN202111231963 2021-10-22

Publications (1)

Publication Number Publication Date
WO2023066350A1 true WO2023066350A1 (zh) 2023-04-27

Family

ID=86027290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/126516 Ceased WO2023066350A1 (zh) 2021-10-22 2022-10-20 Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用

Country Status (8)

Country Link
US (1) US20250243210A1 (https=)
EP (1) EP4421071A4 (https=)
JP (1) JP2024539269A (https=)
KR (1) KR20240110576A (https=)
CN (1) CN116003418A (https=)
AU (1) AU2022370021B2 (https=)
CA (1) CA3235512A1 (https=)
WO (1) WO2023066350A1 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015412A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2024032600A1 (zh) * 2022-08-08 2024-02-15 西藏海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
WO2024173646A1 (en) * 2023-02-16 2024-08-22 Innovo Therapeutics, Inc. Cyclin-dependent kinase degrading compounds
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
US12172992B2 (en) 2022-03-22 2024-12-24 Abbvie Inc. Pyrimidines for degrading Bruton's tyrosine kinase
WO2025036489A1 (zh) 2023-08-17 2025-02-20 海思科医药集团股份有限公司 一种氰基芳香环衍生物及其在医药上的应用
EP4434978A4 (en) * 2021-11-17 2025-03-26 TYK Medicines Inc. Compound for degrading EGFR protein and use thereof
WO2025140369A1 (zh) * 2023-12-26 2025-07-03 标新生物医药科技(上海)有限公司 具有双氮杂环取代的异吲哚啉酮骨架的化合物及其应用
WO2025212165A1 (en) * 2024-04-05 2025-10-09 Board Of Regents Of The University Of Nebraska Targeted heterobifunctional small molecule proteolysis targeting chimeras

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN117229286A (zh) * 2022-06-14 2023-12-15 海创药业股份有限公司 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
TW202428573A (zh) * 2022-10-20 2024-07-16 大陸商西藏海思科製藥有限公司 膦醯衍生物的鹽及晶型和在醫藥上的用途
WO2024083182A1 (zh) * 2022-10-20 2024-04-25 西藏海思科制药有限公司 一种膦酰衍生物的制备方法
CN119451952A (zh) * 2023-06-01 2025-02-14 标新生物医药科技(上海)有限公司 氧代异吲哚啉基取代的四氢嘧啶二酮衍生物及其应用
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途
CN120025326A (zh) * 2023-11-22 2025-05-23 广东东阳光药业股份有限公司 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
CN117756818B (zh) * 2023-12-12 2025-04-29 北京医院 一种戊二酰亚胺类化合物及其制备方法和应用
CN120787222A (zh) * 2024-02-04 2025-10-14 标新生物医药科技(上海)有限公司 基于取代的异吲哚啉酮新颖骨架化合物、含有其的双功能蛋白降解剂及它们的应用
CN120787219A (zh) * 2024-02-04 2025-10-14 标新生物医药科技(上海)有限公司 具有取代的戊二酰亚胺基异吲哚啉酮新颖骨架的化合物及其应用
WO2026061104A1 (zh) * 2024-07-05 2026-03-26 甘李药业股份有限公司 用于雄激素受体靶向降解的化合物和方法
CN118955474A (zh) * 2024-07-29 2024-11-15 浙江爱索拓标记医药科技有限公司 一种放射性同位素碳-14标记的巴德卡鲁胺及其制备方法和应用
CN120004863A (zh) * 2025-02-27 2025-05-16 江苏天士力帝益药业有限公司 一种alk蛋白降解剂及其在抗肿瘤中的应用

Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119357A1 (en) * 2016-12-24 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN110291087A (zh) * 2016-12-01 2019-09-27 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CN110612294A (zh) * 2017-01-31 2019-12-24 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
CN110612297A (zh) * 2017-01-26 2019-12-24 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
CN110741004A (zh) * 2016-12-23 2020-01-31 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
WO2020162725A1 (ko) * 2019-02-07 2020-08-13 한국화학연구원 표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
CN112218859A (zh) * 2018-04-04 2021-01-12 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
WO2021011913A1 (en) * 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CN112262134A (zh) * 2018-04-13 2021-01-22 阿尔维纳斯运营股份有限公司 小脑蛋白配体和包括其的双官能化合物
CN112888681A (zh) * 2018-08-22 2021-06-01 上海睿跃生物科技有限公司 原肌球蛋白受体激酶(trk)降解化合物及使用方法
CN113164775A (zh) * 2018-09-07 2021-07-23 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
WO2021170109A1 (en) * 2020-02-26 2021-09-02 Cullgen (Shanghai) , Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use
WO2021194879A1 (en) * 2020-03-21 2021-09-30 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
WO2021194878A1 (en) * 2020-03-21 2021-09-30 Arvinas Operations, Inc. Selective modulators of mutant lrrk2 proteolysis and associated methods of use
WO2022047145A1 (en) * 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022087125A1 (en) * 2020-10-21 2022-04-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor protein
WO2022098544A1 (en) * 2020-11-06 2022-05-12 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
WO2022109396A1 (en) * 2020-11-20 2022-05-27 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2022133184A1 (en) * 2020-12-20 2022-06-23 Newave Pharmaceutical Inc. Btk degrader
WO2022198112A1 (en) * 2021-03-19 2022-09-22 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
WO2022221673A1 (en) * 2021-04-16 2022-10-20 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071306A1 (en) * 2016-10-11 2018-04-19 Northwestern University Incremental rotary rolling mill and method
TWI793151B (zh) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
WO2020167518A1 (en) * 2019-02-13 2020-08-20 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CN113490528B (zh) * 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
US11485735B2 (en) * 2019-04-25 2022-11-01 Wuxi Shuangliang Biotechnology Co., Ltd. Selective CDK4/6 inhibitor and preparation thereof
FI3835298T3 (fi) * 2019-12-12 2024-07-29 Accutar Biotechnology Inc Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja
CN113292536A (zh) * 2020-02-21 2021-08-24 四川海思科制药有限公司 一种具有降解Bcr-Abl或PARP的化合物及其制备方法和药学上的应用
CN113387931A (zh) * 2020-03-13 2021-09-14 四川海思科制药有限公司 一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
US11739101B2 (en) * 2020-05-06 2023-08-29 Nurix Therapeutics, Inc. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
WO2022099117A1 (en) * 2020-11-06 2022-05-12 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
WO2023023941A1 (en) * 2021-08-24 2023-03-02 Biofront Ltd (Cayman) Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same
WO2023249970A1 (en) * 2022-06-21 2023-12-28 Nikang Therapeutics, Inc. Bifunctional compounds containing pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
CN119451967A (zh) * 2022-06-22 2025-02-14 霖康疗法公司 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物的双功能化合物
US20250367193A1 (en) * 2022-06-22 2025-12-04 Nikang Therapeutics, Inc. Bifunctional compounds containing substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506039A (zh) * 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
CN110291087A (zh) * 2016-12-01 2019-09-27 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
CN110741004A (zh) * 2016-12-23 2020-01-31 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
WO2018119357A1 (en) * 2016-12-24 2018-06-28 Arvinas, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN110612297A (zh) * 2017-01-26 2019-12-24 阿尔维纳斯运营股份有限公司 雌激素受体蛋白水解调节剂及相关使用方法
CN110612294A (zh) * 2017-01-31 2019-12-24 阿尔维纳斯运营股份有限公司 人小脑蛋白配体和包含其的双官能化合物
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN112218859A (zh) * 2018-04-04 2021-01-12 阿尔维纳斯运营股份有限公司 蛋白水解调节剂及相关使用方法
CN112262134A (zh) * 2018-04-13 2021-01-22 阿尔维纳斯运营股份有限公司 小脑蛋白配体和包括其的双官能化合物
CN112888681A (zh) * 2018-08-22 2021-06-01 上海睿跃生物科技有限公司 原肌球蛋白受体激酶(trk)降解化合物及使用方法
CN113164775A (zh) * 2018-09-07 2021-07-23 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
WO2020162725A1 (ko) * 2019-02-07 2020-08-13 한국화학연구원 표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물
WO2021011913A1 (en) * 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
WO2021170109A1 (en) * 2020-02-26 2021-09-02 Cullgen (Shanghai) , Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use
WO2021194878A1 (en) * 2020-03-21 2021-09-30 Arvinas Operations, Inc. Selective modulators of mutant lrrk2 proteolysis and associated methods of use
WO2021194879A1 (en) * 2020-03-21 2021-09-30 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
WO2022047145A1 (en) * 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
WO2022087125A1 (en) * 2020-10-21 2022-04-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor protein
WO2022098544A1 (en) * 2020-11-06 2022-05-12 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
WO2022109396A1 (en) * 2020-11-20 2022-05-27 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2022133184A1 (en) * 2020-12-20 2022-06-23 Newave Pharmaceutical Inc. Btk degrader
WO2022198112A1 (en) * 2021-03-19 2022-09-22 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
WO2022221673A1 (en) * 2021-04-16 2022-10-20 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE Registry CAS; 14 October 2022 (2022-10-14), ANONYMOUS : "2,6-Piperidinedione, 3-[5 -[4-[(2,2-dimethyl-1- piperazinyl)methyl]- 1- piperidinyl]-4-fluoro1,3-dihydro-1-oxo-2 H-isoindol-2-yl]-", XP093059866, Database accession no. 2839672-28-3 *
DATABASE Registry CAS; 17 October 2022 (2022-10-17), ANONYMOUS , XP093059873, Database accession no. 2839757-07-0 *
DATABASE Registry CAS; 19 October 2021 (2021-10-19), ANONYMOUS : "1H-Isoindole-1,3(2H)-dio ne, 2-(2,6-dioxo-3-pi peridinyl)-5-[4-(4- piperidinylmethyl)-1 -piperidinyl]-", XP093059852, Database accession no. 2714477-27-5 *
DATABASE Registry CAS; 19 October 2021 (2021-10-19), ANONYMOUS : "1H-Isoindole-1,3(2H)-dio ne, 2-(2,6-dioxo-3-pi peridinyl)-5-[4-[[1-[2- [4-[6- [5-(1-methylethoxy)- 1H-indazol-3-yl]-4-p yrimidinyl]-1-piperaz inyl]ethyl]-4- piperidinyl]methyl]- 1-piperidinyl]-", XP093059855, Database accession no. 2714476-17-0 *
DATABASE Registry CAS; 23 June 2022 (2022-06-23), ANONYMOUS : "Benzonitrile, 3-chloro-5- [1-[4-[[2-[4-[1-[1-[2- (2,6-dioxo-3-piperidi nyl)- 2,3-dihydro-1,3-diox o-1H-isoindol-5-yl]-3 -piperidinyl]-3-azetid inyl]-1- piperazinyl]-4-pyrimi dinyl]methoxy]phen yl]-1-methylethyl]-", XP093059863, Database accession no. 2776896-94-5 *
DATABASE Registry CAS; 30 September 2021 (2021-09-30), ANONYMOUS : "1H-Isoindole-1,3(2H)-dio ne, 5-[2-(2-aminoeth yl)-3-methyl-1-piperi dinyl]-2- (2,6-dioxo-3-piperidi nyl)-", XP093059849, Database accession no. 2703770-66-3 *
DEGORCE SÉBASTIEN L., TAVANA OMID, BANKS ERICA, CRAFTER CLAIRE, GINGIPALLI LAKSHMAIAH, KOUVCHINOV DAVID, MAO YUMENG, PACHL FIONA, : "Discovery of Proteolysis-Targeting Chimera Molecules that Selectively Degrade the IRAK3 Pseudokinase", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 18, 24 September 2020 (2020-09-24), US , pages 10460 - 10473, XP093059781, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.0c01125 *
HAN XIN, ZHAO LIJIE, XIANG WEIGUO, QIN CHONG, MIAO BUKEYAN, MCEACHERN DONNA, WANG YU, METWALLY HODA, WANG LU, MATVEKAS ALEKSAS, WE: "Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 64, no. 17, 9 September 2021 (2021-09-09), US , pages 12831 - 12854, XP093059787, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.1c00882 *
See also references of EP4421071A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434978A4 (en) * 2021-11-17 2025-03-26 TYK Medicines Inc. Compound for degrading EGFR protein and use thereof
US12172992B2 (en) 2022-03-22 2024-12-24 Abbvie Inc. Pyrimidines for degrading Bruton's tyrosine kinase
WO2024015412A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
WO2024032600A1 (zh) * 2022-08-08 2024-02-15 西藏海思科制药有限公司 一种杂环衍生物及其组合物和药学上的应用
WO2024173646A1 (en) * 2023-02-16 2024-08-22 Innovo Therapeutics, Inc. Cyclin-dependent kinase degrading compounds
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof
WO2025036489A1 (zh) 2023-08-17 2025-02-20 海思科医药集团股份有限公司 一种氰基芳香环衍生物及其在医药上的应用
WO2025140369A1 (zh) * 2023-12-26 2025-07-03 标新生物医药科技(上海)有限公司 具有双氮杂环取代的异吲哚啉酮骨架的化合物及其应用
WO2025212165A1 (en) * 2024-04-05 2025-10-09 Board Of Regents Of The University Of Nebraska Targeted heterobifunctional small molecule proteolysis targeting chimeras

Also Published As

Publication number Publication date
KR20240110576A (ko) 2024-07-15
JP2024539269A (ja) 2024-10-28
AU2022370021B2 (en) 2026-04-16
US20250243210A1 (en) 2025-07-31
EP4421071A4 (en) 2026-03-11
EP4421071A1 (en) 2024-08-28
CN116003418A (zh) 2023-04-25
CA3235512A1 (en) 2023-04-27
AU2022370021A1 (en) 2024-05-09

Similar Documents

Publication Publication Date Title
WO2023066350A1 (zh) Crbn e3连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
CN112778276B (zh) 作为shp2抑制剂的化合物及其应用
ES3030549T3 (en) Compounds useful as inhibitors of atr kinase
WO2023104155A1 (zh) E3泛素连接酶配体化合物、基于该配体化合物开发的蛋白降解剂及它们的应用
US20250206752A1 (en) Pi3k inhibitors
US20180230152A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
WO2024032689A1 (zh) 基于异吲哚啉取代戊二酰亚胺骨架的化合物及其应用
WO2015022926A1 (ja) 新規な縮合ピリミジン化合物又はその塩
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
CN120202200A (zh) 基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
WO2024140637A1 (zh) 氧代异吲哚啉基取代哌啶二酮衍生物及其应用
TW201831476A (zh) 吡啶并〔３，４－ｄ〕嘧啶衍生物及其藥學上所容許之鹽
WO2023284703A1 (zh) 基于布鲁顿酪氨酸激酶配体设计的蛋白降解化合物及其应用
TW202400589A (zh) 四氫異喹啉異雙功能ｂｃｌ—ｘｌ降解劑
CN119630669A (zh) 硫代的戊二酰亚胺基异吲哚啉酮衍生物、含有其的双功能蛋白降解剂及它们的应用
WO2024245444A1 (zh) 氧代异吲哚啉基取代的四氢嘧啶二酮衍生物及其应用
CN112390785A (zh) 一种bet家族溴域抑制剂环衍生物及其制备方法和药学上的应用
CN116589445B (zh) 基于喹唑啉取代戊二酰亚胺骨架的化合物及其应用
WO2024051766A1 (zh) 基于cereblon蛋白设计的分子胶化合物及其应用
WO2024140638A1 (zh) 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用
WO2023131118A1 (zh) 基于bcl-2家族蛋白配体化合物开发的蛋白降解剂及它们的应用
HK40085637A (en) Crbn e3 ligase ligand compounds, protein degraders developed based on the ligand compounds, and their applications
WO2025026422A1 (zh) 芳基或杂芳基取代的戊二酰亚胺衍生物及其应用
AU2024294043A1 (en) Glutarimide isoindolinone skeleton-based compound
WO2025016351A1 (zh) 基于硫代的戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22882955

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2024524582

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3235512

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 18703316

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: AU2022370021

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 202417036171

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2022370021

Country of ref document: AU

Date of ref document: 20221020

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20247016562

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022882955

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022882955

Country of ref document: EP

Effective date: 20240522

WWP Wipo information: published in national office

Ref document number: 18703316

Country of ref document: US